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ABSTRACT 
 Transporters dynamically expressed at the mammary gland transport critical 
nutrients into the breast milk of nursing mothers to meet the nutritional demands of the 
suckling infant.  However, xenobiotics may interact with these transporters to potentially 
alter the nutrient composition of milk and compromise neonatal nutrition.  The aim of 
the present study was to quantitatively evaluate the constitutive expression of various 
nutrient transporters in whole mammary gland tissue and mammary epithelial organoids 
(MEO) isolated from female Sprague-Dawley rats at various stages of pregnancy, 
lactation, and involution.  Furthermore, the study’s aim was to determine if appropriately 
cultured mammary epithelial organoids (MEO) maintain in vivo transporter expression 
to lay down critical groundwork for the development of an in vitro screening tool 
assessing xenobiotic-nutrient transporter interactions.  The following transporters were 
evaluated using quantitative real-time reverse transcription polymerase chain reaction 
(QRT-PCR): multidrug resistance protein (Mdr) 1a, 1b; multidrug resistance-like protein 
(Mrp) 1; organic cation transporter (Oct) 1; organic cation/carnitine transporter (Octn) 1, 
2, and 3; concentrative nucleoside transporter (Cnt) 1, 2, and 3; equilibrative nucleoside 
transporter (Ent) 1, 2, and 3; nucleobase transporter (Ncbt) 1 and 2; oligopeptide 
transporter (Pept) 1 and 2; methotrexate carrier (Mtx) 1; divalent metal transporter 
(Dmt) 1; and the milk protein β-casein.  Transporter expression patterns in MEO 
differed from whole tissue for β-actin, Mdr1a, Mdr1b, Oct1, Octn3, Ent3, Cnt1, Cnt3, 
Ncbt1, Pept2, Mtx1, and β-casein.  This brings into question whether whole mammary 
gland tissue is truly appropriate for an understanding of transporter expression in the 
mammary epithelium.  Nevertheless, four general transporter expression patterns 
emerged in isolated MEO: decline throughout lactation (Mdr1a, Mdr1b, Mrp1 & Dmt1), 
increase throughout lactation (Cnt1 & Octn3), increase in early lactation (Oct1, Octn2, 
Ent1, Cnt2, Cnt3, Pept2 & Mtx1) and constant expression throughout lactation (Octn1, 
Ent2, Ent3, Ncbt1, Ncbt2 & Pept1). These expression patterns will provide insight into 
the critical windows of nutrient delivery to the breast milk to provide adequate 
nutritional stimuli to the suckling infant. Furthermore, MEO cultured in an extracellular 
matrix-rich environment maintained transporter expression at the mRNA level, which 
underscores the potential of the primary MEO in vitro model system as a screening tool 
 ii 
for xenobiotic-transporter interactions at the mammary gland.  Transporter expression 
patterns in MEO were unique for each transporter evaluated.  This information 
accompanied by an in vitro screening tool may allow for predictions of xenobiotic 
interference with breast milk composition to help safeguard infant health. 
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LITERATURE REVIEW 
∑ 
 
1.1.  Introduction 
illions of years of evolution have transformed the mammary gland from an 
accidentally hypertrophied gland, whose secretions lacked any basic 
nutritional value into an extremely specified and efficient organ which 
now provides all mammalian young with a highly regulated nutrient-rich secretion1, 2.  
However, the protein-mediated pathways that regulate the transport of critical macro- 
and micronutrients into the milk3, 4 and consequently govern the specificity of milk 
composition have received limited attention.  Yet without a fully developed knowledge 
of many of the critical processes responsible for the regulation of the nutrient 
composition of maternal milk, breastfeeding is nevertheless being promoted worldwide 
because of the proposed health benefits over that of infant formula5-7.  In developed and 
underdeveloped countries alike, breastfeeding is promoted as the best form of infant 
feeding. However, in underdeveloped countries plagued with poor nutrition and/or 
environmental toxins, and developed countries with similar environmental risks and 
copious use of pharmaceuticals, breastfeeding is encouraged with very few 
contraindications8-14.  What is not well known is whether environmental factors, such as 
environmental toxins or exogenous xenobiotic use can negatively influence the 
composition of breast milk.  Through breastfeeding, mothers in a nutrient scarce 
environment pass a poor-nutrition phenotype to her progeny leading to a permanent 
M 
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reorganization of the neonatal system15-20.  In addition, if drugs/toxins are involved, the 
knowledge of drug/toxin levels in the breast milk is inadequate, despite contemporary 
thought to the contrary, for risk/benefit assessments when mothers who wish to 
breastfeed require pharmacotherapeutic management for chronic disease conditions.  
This is because many of these clinically relevant xenobiotics, which are not 
contraindicated during breastfeeding, are substrates for nutrient-specific transporters. An 
interaction between a xenobiotic and a nutrient transporter may compromise the nutrient 
composition of maternal milk leading to an altered neonate phenotype.  It is not known 
under what circumstances these exposures to xenobiotics will compromise milk 
composition, and pose a significant nutritional risk to the nursing neonate.  A 
comprehensive investigation of the temporal expression of mammary gland transport 
proteins will aid in assessing when a potential xenobiotic-transporter interaction may 
occur at the lactating mammary gland.  Furthermore, an in vitro screening tool will help 
to screen such interactions, providing a critical assessment to help safeguard both mother 
and infant health. 
 
1.2.  Background 
1.2.1.  Breastfeeding – Evolutionary Perspectives  
 
“Is it conceivable that the young of any animal was ever saved 
from destruction by accidentally sucking a drop of scarcely 
nutritious fluid from an accidentally hypertrophied cutaneous 
gland of its mother?” 
- St. George Mivart 21 
 
The mammary gland is one of the most remarkable developmental systems in 
human and animal physiology, and despite the fact that the mammary gland and 
lactation are the sole defining characteristics of all mammals, it’s origin and evolution is 
largely a mystery.  Postulated to have evolved from a common ancestor as early as the 
Jurassic period1, this gland may have evolved from a holocrine sebaceous gland, an 
exocrine sweat gland, or an apocrine scent gland1, 2.  However, regardless of the origin 
 3 
of this gland, the nutrient-rich secretions that it now provides serve as a feeding-station 
for the suckling young of all mammals.  
 Our evolved reproductive strategy has developed in the wake of our primate 
ancestors.  We compromise large litter sizes for a longer gestation period and 
considerably longer lactation periods.  The benefits are speculatory, but are best summed 
up by Malcolm Peaker2, who speculates that the long period of parental control had a 
very distinct evolutionary advantage:  Long gestational periods and birth through the 
pelvic route limited infant size to an extent that they were developmentally immature, 
specifically in neural development.  Neural plasticity allowed for a learned adaptation to 
the environment and has therefore demanded prolonged parental care beyond that of 
lactation in higher order animals such as primates and Homo sapiens2.  This “prolonged 
care” hypothesis has allowed us to gleam information about the mother-neonate 
interaction during lactation in that it may not be just a nutrient-providing interaction but 
may play a significant role in ensuring the developing offspring are programmed to be 
the most reproductively fit (for survival) as possible to thrive by accurately reflecting the 
immediate environment (i.e. nutritional resources)2. 
 The nutrient messages in maternal milk may accurately reflect the nature of the 
immediate maternal environment – a signal to the neonate of what is to be expected after 
weaning – to enhance the success of offspring survival2. Or milk may merely provide 
adequate nutrients to immature animals who are unable to thrive on their own to avoid 
destruction2.  Regardless of the proposed role of the mammary gland in lactation and 
infant feeding/signaling, lactation is without a doubt an extremely critical and important 
stage in mammalian development and survival.  Our current knowledge base of 
mammary gland function precludes an adequate understanding of the roles of this 
critical organ in the development and survival of our young. 
1.2.1.1.  Early Life Nutrition and its Consequences in Later Life 
 The majority of mammals, specifically the higher order mammals such as 
humans and primates, have a distinct evolutionary advantage over many other species. 
Mammals are born very neural-plastic and metabolically immature and can, therefore, 
rapidly and permanently adapt to the external environment in a manner best suited for 
survival2.  Mammals all evolved from a common ancestor millions of years ago; 
 4 
however, we all exist in very different and ever-changing environments and we readily 
and sometimes unknowingly adapt to these subtle environmental insults as they 
transpire.  Programmed information must be passed on to our young to ensure their 
survival1, 2.  The mammary gland is the sole nutrient-providing source for mammalian 
neonates and may act as one of the many signaling mechanisms to indicate to the 
offspring what to expect in the current environment, at least with respect to readily 
available food sources.  If food sources are in abundance, litters are allowed to grow and 
feast with no limits.  However, if food sources become immediately scarce, litters must 
adapt to an environment low in resources.  This phenomenon was initially described 
over 40 years ago when rat litters from two mothers were manipulated16, 17.  One dam 
received more pups than she could handle, and the other dam received only a very small 
litter.  Upon weaning, animals from the large litter group with limited milk availability 
were significantly smaller than those from the small litter group where milk was in 
abundance.  Furthermore, as animals were introduced to normal rat chow, the smaller 
animals from the large litter group continued to remain small in size relative to the small 
littered animals indicating a permanent reorganization of metabolism in the smaller 
animals16, 17.  Although genetic factors determine the genotype of a species, other 
mechanisms in addition to genetic factors can play a role in determining the phenotype.  
These non-genetic, or epigenetic mechanisms, play a significant role determining the 
organization of every physiological system18.  In fact, the alterations in metabolism from 
such epigenetic mechanisms are well established, and can cause significant long-term 
alterations in metabolism18.   
 Since the mammary gland is the sole nutrient-providing organ for mammals in 
the initial stages of life and has evolved numerous adaptive mechanisms to permanently 
organize the physiology of the offspring to ensure their immediate survival to reproduce, 
we must begin to appreciate the dynamics of this system and question the consequences 
that these dynamics may have on the offspring in later life. 
1.2.1.2.  Maternal Adaptations to Mammary Gland Differentiation and Milk Secretion 
 The status of the mammary gland is dependent on reproductive state and the 
demands of the nursing young for milk.  The mammary gland is a hormonally regulated 
system dependent on endocrine control from reproductive hormones (estrogen, 
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progesterone, placental lactogen, prolactin, and oxytocin), metabolic hormones (growth 
hormones, corticosteroids, thyroid hormone, and insulin), and mammary hormones 
(growth hormone, prolactin, leptin, and PTHrP)22.  The development of the mammary 
gland from virgin to a fully functional, milk-secreting organ is due to many hormonal 
interventions and has been recently reviewed22-24.  My thesis will only cover the basics 
with respect to mammary gland function during pregnancy and lactation and will not 
review the mammary gland from embryonic development to puberty. 
 The onset of pregnancy stimulates a significant remodeling process within the 
mammary gland with continuous changes leading up to lactogenesis and persisting 
throughout the entire lactation period; lactogenesis phase I and II, respectively (Figure 
1.1).  Lactogenesis phase I occurs during mid-pregnancy with the proliferation and 
differentiation of the terminal end buds and the expression of most (but not all) genes 
responsible for milk production in the alveolar cells22.  Lactogenesis phase I is 
controlled primarily by the reproductive hormones progesterone, prolactin, placental 
lactogen, and growth hormone22.  At the time of parturition, lactogenesis phase II is 
initiated.   
 Lactogenesis phase II is characterized by the expression and upregulation of 
additional genes responsible for milk production in the alveolar cells and the onset of 
colostrum formation. Soon thereafter copious production and secretion of mature milk 
ensues after the closure of tight junctions between milk-producing epithelial cells in the 
full compliment of lobular alveolar complexes22.  Lactogenesis phase II is established 
with high levels of prolactin and an immediate withdrawal of progesterone at 
parturition22.  Phase II of lactogenesis is maintained by the constant removal of milk 
from the mammary gland lumen (suckling), high levels of prolactin (maintenance of 
milk production from alveolar cells), and a constant supply of oxytocin (contributing to 
the milk-ejection reflex by stimulating myoepithelial cell contraction).  The regulation 
and feedback patterns of each lactation hormone are great and will not be discussed here 
in any detail; however, Table 1.1 provides a summary of the responsibilities of each 
hormone during lactogenesis. 
 Milk synthesis and secretion places tremendous energy demands on the mother. 
All mammals have developed their own “lactation strategy” to meet these high-energy 
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demands, regardless of each animals’ lifestyle during the lactation period25.  Animals 
who remain sedentary and do not eat for the duration of the lactation period most 
certainly employ a much different strategy than those animals that maintain eating 
and/or hunting practices over this period, as these non-fasting animals can rely on both 
endogenous energy stores and exogenous energy sources to provide the fuel required for 
milk synthesis25. 
 
 
Figure 1.1 – Simple representation of the mammary gland structure in the virgin state 
(A) and the remodeling that occurs during lactogenesis (B) with emphasis given to the 
mammary alveoli (insert from B).  Each lobular alveolar complex is composed of 
clusters, primarily of milk-producing mammary epithelial cells, which secrete milk into 
a defined lumen to be transferred into milk collecting ducts and excreted from the breast 
during breastfeeding.  The figure is presented to emphasize the changes in mammary 
alveoli and does not capture the adipose tissue, blood supply, or myoepithelial cell 
composition of the mammary gland. 
 
 
A 
B 
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Table 1.1 – Roles and responsibilities of hormones released during lactogenesis phase I 
and II22. 
 
Hormone Responsibility 
Reproductive Hormones 
Estrogen Ductal morphogenesis & possible induction of prolactin 
Progesterone Alveolar proliferation in lactogenesis I and withdrawal 
stimulates lactogenesis II 
Placental Lactogen Support of corpus luteum during lactogenesis I 
Prolactin Alveolar proliferation & maintenance of lactation during 
lactogenesis II 
Oxytocin Milk-ejection reflex during lactogenesis II 
Metabolic Hormones 
Growth Hormone Ductal morphogenesis through IGF-1 
Corticosteroids Increase during lactogenesis I and II, possible role for 
nutrient flux 
Thyroid Hormones Increase milk protein synthesis & enhance receptiveness to 
growth hormone and prolactin 
Insulin Unknown.  Possible substitute for IGF-1 (in culture) 
Mammary Hormonesa 
Growth Hormone Ductal morphogenesis through IGF-1 
Prolactin Maintenance of lactation during lactogenesis II 
Leptin Fat mobilization during lactogenesis II 
PTHrP Mobilizing bone calcium during lactogenesis II 
a During lactogenesis, the mammary gland becomes an endocrine organ, synthesizing it’s 
own compliment of hormones for local paracrine or autocrine roles. 
 
 Adipose tissue is the major energy-dense tissue with fatty acids providing more 
than 2-times the energy per gram than any other energy source (carbohydrates and 
proteins).  Fatty acids then play a leading role in providing the energy requirements to 
drive milk production and sustain lactation25, and therefore females have adapted 
mechanisms to store copious amounts of fat during gestation that allow a distinct 
evolutionary advantage25.  Whereas some animals must rely on an environment with an 
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abundance of resources, we are able to reproduce in environments even where resources 
run low.  Even though humans reproduce and thrive in environments where resources 
are plenty, the copious amounts of adipose tissue accumulated during pregnancy greatly 
contribute to neonatal fuel sources, a way of optimizing maternal resources. 
 The maternal system must use both stored and exogenous resources to drive 
many physiological processes, which provide the neonate with adequate nutrients in a 
manner as to not completely disrupt maternal stores25, 26.  Therefore, the mother must 
adapt other mechanisms that will provide adequate amounts of critical nutrients to 
overcome the high-energy demands of breastfeeding.  Significant changes occur in the 
gastrointestinal tract of the mother throughout lactation.  Gastric emptying rate, and 
gastrointestinal transit are significantly increased during the first 2 weeks of lactation27 
to accommodate the large nutrient demands of the nursing neonate.  In addition, the 
mucosal surface area of the maternal small intestine is significantly enhanced in the 
proximal duodenum and decreases distally28.  The increased surface area in the 
duodenum indicates a much greater capacity to absorb dietary nutrients.  In fact, the 
majority of weight retention in mice after parturition was attributed to the increase in 
splanchnic organ mass and these mice showed a significantly increased ability to 
transport D-glucose, D-fructose, and L-proline29.   In addition to macronutrient 
transporters, intestinal transporters responsible for the uptake of micronutrients such as 
calcium30 and zinc31 are also significantly upregulated during lactation.  Furthermore, 
the intestinal multidrug resistance like protein member 2 (Mrp2; a member of the ATP-
binding cassette transporter family (ABC)), responsible for the efflux of various 
xenobiotics into the intestinal lumen, is significantly increased throughout the lactation 
period indicating an adaptive mechanism to decrease the transport of dangerous 
chemical entities into maternal blood to be delivered to the neonate32.  Many other 
pharmacokinetic parameters are also increased during lactation in addition to the 
changes in gastrointestinal absorption.  Increases in plasma protein levels, cardiac 
output, total body water, and total blood volume will ultimately affect the appearance of 
both wanted, and unwanted compounds at the mammary epithelia33 where all nutrient 
components of milk are secreted.  The mammary gland has adapted numerous transport 
mechanisms that accommodate milk composition, which include major macronutrients 
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such as the various amino acids and glucose, and also the micronutrients such as the 
numerous milk ions, where the transport systems regulating the appearance of these 
nutrients has been extensively reviewed34.  Recently it was also established that these 
transport systems do change throughout lactation as they contribute to a specialized 
breast milk formulation3.  The contribution of these transport systems to milk 
composition will be discussed shortly.  However, it appears from a recent report3 that the 
regulation of transporter expression of the SLC and ABC transporters is not only 
complex, but highly structured such that all the resources of the epithelial cells are 
dedicated to providing nutrient-rich secretions.  Genes that do not contribute to nutrient 
secretions (i.e. MDR & MRP) are not supported during the high-energy demands of 
lactation3. 
 The maternal system has adapted many mechanisms during lactation to not only 
provide the neonate with vast amounts of critical macro- and micronutrients for growth 
and development without compromising maternal homeostasis, but it has also evolved 
mechanisms to limit infant exposures to potentially harmful xenobiotics.  
 
1.2.2.  Messages in Milk – Breast is Best 
 Lactation is a continuation of the “crosstalk” between mother and neonate seen 
during gestation.  However, during lactation the mother may now be the dominant 
driving force governing infant nutrition through the composition of the breast milk, 
rather than the bi-directional transfer of nutrients across the placenta during gestation.  
Maternal milk is an extremely complex biological fluid that is composed of thousands of 
nutrient and non-nutrient components that compartmentalize in one of the phases of the 
milk; aqueous phase, colloidal dispersions of casein molecules, emulsions of fat 
globules, fat-globule membranes, and live epithelial cells35, each of which play a key 
role in infant development.  Furthermore, the nutrients present in human milk (i.e. iron36, 
zinc37, proteins/growth factors38& fats39) are significantly better absorbed in the neonate 
making it far superior to infant formula due to the unique composition and easy 
digestibility40.  
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1.2.2.1.  Critical Milk Constituents 
1.2.2.1.1.  Macronutrients 
 Macronutrients are nutritional components of the diet that can independently 
and/or collectively provide the metabolic energy necessary to maintain all metabolic 
functions in a living organism.  These components include, but are not exclusive to the 
proteins, carbohydrates, and fats as the major nutrient substrates in our diets.  
Macronutrient roles in the neonate have been largely elucidated and any disturbance in 
the balance of these nutrients in the breast milk has very detrimental outcomes in the 
nursing infant15-17, 19, 41, 42.  For instance, rat pups exposed to low or no-protein breast 
milk demonstrate a significant and permanent decrease in feeding pattern through altered 
circulating insulin and leptin levels42, and a significant alteration in pancreatic β-cell 
function causing permanent, irreversible effects on glucose homeostasis15, 41.  In 
addition, mothers exposed to a high carbohydrate diet during the lactation period passed 
on the high carbohydrate phenotype (chronic hyperinsulinemia and adult-onset diabetes) 
to the progeny indicating a permanent programming of β-cell function19.  A number of 
studies have evaluated the nutritional excess or deficiency of macronutrients.  The 
findings of these studies have been extensively reviewed43-46, and is not the focus of my 
thesis work, rather my work will focus on the micronutrients. 
1.2.2.1.2.  Micronutrients 
 Unlike macronutrients, the micronutrients are needed in only very minor 
quantities in the diet to maintain health but do not directly contribute to overall 
metabolic fuel.  Rather micronutrients contribute to a number of biochemical pathways.  
These components include vitamins, minerals, nucleosides and nucleotides, smaller 
peptides, anions, and cations47.  Deficits or excesses of micronutrients are equally as 
detrimental as those of the macronutrients and only recently are we uncovering the 
effects of some of these micronutrient deficiencies or excesses during lactation due to 
maternal health status and the effect on the developing offspring48.  The greater numbers 
of studies evaluating micronutrients are focused primarily on essential metal49-54 and 
vitamin48 excess or deficiency in early life development, however deficiencies in other 
micronutrients are well documented.  Although the immediate effects of certain 
deficiencies are limited and are only visible in later life, other critical micronutrient 
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deficiencies (i.e. metal55 or vitamin D56)  are immediately visible and cause irreversible 
damage.  Findings from such studies is driving research into exogenous maternal 
supplementation of certain vitamins and trace elements49 to compensate for possible 
maternal deficiencies in these trace compounds. However, without a proper knowledge 
of the exact requirements of these components, supplementation guidelines may be 
misleading47.  Unfortunately, micronutrient deficiencies in the mother are not always 
correlated with similar micronutrient deficiencies in the breast milk and therefore, may 
be difficult to detect.  For instance, milk iron concentrations remain unaltered until the 
deficiency/excess are extreme52, however even minor iron deficiencies cause an altered 
expression of the major milk proteins, the whey-acidic protein (WAP) and β-casein57.  
Therefore, monitoring milk nutrient levels may not always reflect maternal nutrient 
deficiencies.  However, these nutrient deficiencies can potentially alter maternal milk 
concentrations, even when deficiencies are minor57.  Furthermore, we lack a basic 
understanding of the immediate roles of other critical micronutrients in the mammary 
gland, if any, and how altered breast milk levels may influence the proper ontogeny of 
the neonatal system. 
 
1.2.3.  Transport of Milk Constituents 
1.2.3.1.  Mammary Gland Secretion Routes 
 The macro- and micronutrients exploit a variety of transport routes across the 
mammary epithelia into the breast milk.  The excretion of these critical milk constituents 
is dependent on an established cellular architecture within the epithelium of the 
mammary gland; specifically the formation of new cytoskeleton components, 
interactions with neighboring cells (formation of tight junctions), and interactions 
between the epithelial cell and the extracellular matrix proteins58, 59. Once this 
architecture is established, the mammary epithelium becomes an extremely efficient 
medium to transport constituents into and out of breast milk.  Each one of the critical 
nutrient and non-nutrient components of breast milk reaches the mammary gland lumen 
by its own unique entry process: I Milk fat globule secretion, II paracellular pathway, III 
protein-mediated transport pathway, IV exocytotic pathway and V the transcytotic 
pathway (Figure 1.2)60.  
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 The majority of literature to date discusses the changes that occur during 
lactation to only few of these major pathways such as the paracellular pathway, 
transcytosis of large molecules, milk-fat secretion, and protein-mediated transport of 
macronutrients60-67.  However, with the exception of essential metal transporters52, 53, 68-
71, the changes in the protein-mediated pathways with respect to micronutrient elements 
have been largely overlooked.  Therefore, the remainder of my thesis will focus attention 
on the protein-mediated transport pathways (pathway III; Figure 1.2) of micronutrients 
and put into perspective how the marked dynamics of this pathway during lactation 
make it a critical pathway in determining the highly specialized micronutrient 
composition of maternal milk. 
 
 
Figure 1.2 – The major secretion mechanisms of milk components from the polarized 
epithelium of the lactating mammary gland.  I Milk fat globule secretion, II paracellular 
pathway*, III protein-mediated transport pathway, IV exocytotic pathway, and V 
transcytotic pathway. *Paracellular movement of solutes is limited to very early 
lactation during colostrum formation, however after the formation of tight junctions and 
the formation of mature milk, the paracellular pathway is non-existent for most solutes. 
 
1.2.4.  Transporter Expression in Lactating Mammary Epithelial Cells 
 Hormonal regulation causes significant changes in the mammary gland of 
pregnant mothers including cellular proliferation and differentiation into a polarized 
epithelium, the onset of milk production from mammary alveolar epithelial cells22, 72 and 
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significant changes in the transporter mosaic that allows the transport of nutrients and 
endogenous compounds across the mammary epithelium3.  Studies have shown the 
altered expression of many transporters associated with the mammary gland, specifically 
the altered expression of nutrient transporters that allow the passage of nutritive 
elements into maternal milk3, 34, 52, 61, 67, 73-76.  A recent study3 showed that human 
lactating mammary epithelial cells express a much different transporter mosaic than do 
non-lactating mammary epithelium.  This altered expression mosaic includes changes in 
transporter mRNA expression levels of members in both the ATP-binding cassette 
transporter (ABC) family and the solute-carrier transporter (SLC) family. 
1.2.4.1.  ATP-Binding Cassette Transporters (ABC) 
 The ATP-binding cassette transporter superfamily consists of transporters that 
are characterized as primary active transporters, which use the coupling of ATP to drive 
the movement of substrate against or independent of a concentration gradient (Figure 
1.3).  These transporters are primarily efflux transporters, and can be expressed at the 
apical or basolateral plasma membrane compartments of a polarized epithelium and 
contribute to the removal of large lipophilic compounds from the cell and deposit them 
into a lumen or back into the blood stream77. 
 Depending upon their localization in a polarized epithelium, then, these 
transporters can either accumulate compounds in a particular tissue or play a protective 
function by impeding the access of compounds to certain tissues, creating a privileged, 
protected compartment.  For instance, P-glycoprotein (MDR) and the multidrug 
resistance-like proteins (MRP), both major players in xenobiotic disposition, are 
dynamically expressed at critical physiological barriers such as the gastrointestinal tract 
and blood-brain barrier, and contribute to multidrug resistance by governing the active 
efflux of xenobiotics78-81.  Therefore, the expression of these proteins in the mammary 
gland will provide insight into the susceptibility of the mammary gland to xenobiotic 
attack, where the decrease in expression throughout lactation may be correlated with a 
decline in the ability of xenobiotics to penetrate the mammary gland lumen. 
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Figure 1.3 – A simplified representation of the mechanism of substrate removal from 
the cell by the ATP-binding cassette superfamily of proteins.  I, the binding of ATP to 
the ATP-binding domains of the protein; II, substrate movement across the plasma 
membrane; III, ADP and inorganic phosphate are released from the ATP-binding 
domains and the cycle can be repeated. The active site for substrate binding is postulated 
to exist within the lipid bilayer (dashed arrow). 
  
1.2.4.2.  Solute-Carrier Transporters (SLC) 
 Classified as secondary or tertiary-active transporters, the transporters in the SLC 
transporter superfamily do not directly use ATP as a driving force for the movement of 
substrates, but rather take advantage of a previously established concentration gradient 
within the cell, or they actively create a concentration gradient for the transport of the 
desired substrate.  SLC transporters can be facilitators (allowing for solute movement 
into and out of the cell based on an existing concentration gradient), 
exchangers/antiporters (removal of a compound drives the uptake of the wanted 
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substrate), or cotransporter/symporters (simultaneous transport of a compound that 
creates an energy-driving force and the wanted substrate; Figure 1.4)82.   
  
 
Figure 1.4 – A simplified representation of the mechanisms of substrate uptake by 
members of the solute carrier superfamily (SLC).  I facilitated transporter, II 
exchangers/antiporters, III cotransporter/symporter.  Arrows indicate the direction of 
movement of the desired substrate (solid arrows; green substrate) and secondary-active 
solute (dashed arrows; grey solute). 
 
 The SLC proteins are classified according to their endogenous role of solute 
transport, and consist of the following major families of transport proteins:  Organic 
anion transporters; organic cation transporters; nucleoside/nucleobase transporters; 
oligopeptide transporters; and essential metal transporters3, 83, 84.  These transporters are 
primarily uptake proteins and can be expressed at either the apical and basolateral 
compartments of a polarized epithelium.  For instance, the concentrative nucleoside 
transporters are expressed at the luminal surface of absorptive epithelia (i.e. 
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gastrointestinal and renal barriers) and contribute to the uptake of critical nutrient 
components85, whereas the equilibrative nucleoside transporters are expressed 
basolaterally in these epithelial barriers and contribute to the bi-directional transport of 
nucleosides86.  Therefore, the expression of these transporters in the mammary gland 
may provide insight into their transport roles throughout lactation. 
1.2.4.3.  Transporter Role in Nutrient Transport into Lactating Mammary Epithelial 
Cells 
 The roles and cellular localization (apical or basolateral cell compartment) of 
both the ATP and SLC superfamilies in solute transport have been elucidated for many 
polarized epithelial barriers (i.e. kidney, liver, blood-brain barrier, intestine, lung, etc.) in 
many different species87.  The cellular localization of the protein combined with the 
knowledge of the protein function gives insight into the role of this protein in the 
accumulation and/or removal of specific substrates from the cells at each barrier. 
However, despite the large amount of effort put into the evaluation of these transporters, 
there has been very limited work dedicated to the cellular localization of these 
transporters in the mammary gland.  Knowledge of the movement of specific 
constituents from the blood stream into maternal milk (or visa versa) based on cellular 
localization would prove to be an invaluable resource.  
 Each nutrient transporter has a specific substrate profile and role that is reflected 
in its nomenclature (Table 1.2)83, 84; however, this information is inadequate in 
completely determining how these proteins contribute to the composition of maternal 
milk.  The missing puzzle piece is, of course, the cellular localization of these 
transporters and their expression levels during different stages of lactation.  As stated 
previously, localization and function taken together can provide insight into the role that 
a transporter will play in a given tissue or barrier.  Figure 1.5 shows the cellular 
localization of transporters from both the ABC and SLC transporter superfamilies in a 
typical polarized barrier epithelium. 
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Table 1.2 – Nutrient substrate profiles and mechanism of action for transporters from 
the ATP-binding cassette (ABC) and the solute carrier (SLC) superfamilies.  A complete 
list of known SLC and ABC transporters is also available83, 84. This list identifies those 
transporters assessed in this thesis research. 
 
Transporter Function/Coupling Ionsa Nutrient Substrate Profile 
Mdr1a Efflux/ATP Unknown 
Mdr1b Efflux/ATP Unknown 
Mrp1 Efflux/ATP Unknown 
Oct1 F Organic cations88 
Octn1 F or E/H+ Organic cations/carnitine88 
Octn2 C/Na+ Organic cations/carnitine88 
Octn3 C/Na+ Organic cations/carnitine89 
Cnt1 C/Na+ Pyrimidines & adenosine85 
Cnt2 C/Na+ Purines, uridine85 & adenosine90  
Cnt3 C/Na+ Purines & pyrimidines85 
Ent1 F Purines & pyrimidines86 
Ent2 F Purines, pyrimidines, & nucleobases86 
Ent3 Unknown Purines, pyrimidines, & nucleobases86 
Ncbt1 C/Na+ L-Ascorbic acid & nucleobases91 
Ncbt2 C/Na+ L-Ascorbic acid & nucleobases91 
Pept1 C/H+ Di- & tri-peptieds92 
Pept2 C/H+ Di- & tri-peptides92 
Mtx1 C/Na+ Folate/methotrexate93 
Dmt1 C/H+ Non-heme (ferrous) iron94 
a (F facilitated transporter, E exchanger, C cotransporter) 
 
  
 Although Figure 1.5 shows cellular localization of ABC and SLC transporters in 
a typical polarized barrier epithelium (i.e. intestine, kidney, liver, brain), it may not 
accurately reflect the localization of these transporters in the mammary epithelium.  For 
instance, the multi-drug resistance like protein, Mrp1 has different cellular expression 
patterns depending on the polarized barrier tissue.  Mrp1 is expressed apically at the 
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blood-brain barrier, however expressed at the basolateral membrane compartment in 
most other polarized barrier tissues (intestine, kidney, blood-testis, blood-CSF and 
blood-placental)95.  Nevertheless, these transporters are present in the mammary gland4, 
expressed at different levels between non-lactation and lactation states3 indicating some 
sort of regulatory mechanism, and do transport critical micronutrients (Table 1.2) which 
contribute to the optimal composition of maternal milk. 
 
 
 
Figure 1.5 – Cellular localization of transporters from the ATP-binding cassette (ABC) 
and solute carrier (SLC) superfamilies of transport proteins in a typical polarized tissue. 
Transporters shown at both apical and basolateral surface are expressed at either surface 
depending on the tissue epithelium and are not expressed in both compartments in the 
same tissue. 
 
1.2.4.4.  Xenobiotic Interference with Transporter Function 
 All transporters have a preferred substrate profile; a profile that is grounded on 
physicochemical characteristics.  Nevertheless, many foreign compounds (i.e. 
xenobiotics or environmental toxins) possess physicochemical characteristics similar to 
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the preferred substrates of a transporter.  Similar characteristics between a preferred 
substrate and the foreign compound may result in a competition for the transporter active 
site, and if the foreign compound out-competes the substrate, it can lead to an 
unfavorable dynamic. 
 The classic example is the interplay between intestinal p-glycoprotein (MDR) 
and its enzyme-counterpart, CYP3A4.  Inhibition of intestinal MDR or CYP3A4 
function has lead to altered pharmacokinetics/toxicokinetics by eliminating the intestinal 
first-pass effect96.  For instance, administration of 6',7'-dihydroxybergamottin (DHB), 
one of the components of grapefruit juice (a potent intestinal CYP3A4 inhibitor), along 
with a drug, significantly increased systemic drug levels which can lead to serious 
hepatotoxicity97.  However, this inhibitory effect is not exclusive to xenobiotic 
transporters and can be seen in nutrient-specific transporters as well.  For instance, the 
substrate profile of the organic cation/carnitine transporter, OCTN2, is nearly exclusive 
to organic cations and carnitine. However, clinically relevant drugs such as the β-lactam 
antibiotics98 and the oral hypoglycemic agents, sulfonylureas (used in the management 
of type 2 diabetes)99, are also substrates for OCTN2.  These xenobiotics have the 
capacity to occupy the active site of OCTN2 in the renal proximal tubule, preventing the 
reabsorption of filtered carnitine resulting in an increased urinary carnitine excretion and 
ultimately an acquired carnitine deficiency98, 99.  Carnitine deficiency can lead to many 
metabolic conditions including progressive cardiomyopathy, encephalopathy, and 
skeletal myopathies, often in a very short period of time (3-6 weeks)20. Acquired 
carnitine deficiency due to xenobiotic interactions with OCTN2 is a particularly 
poignant example of a very serious adverse health outcome following a xenobiotic-
nutrient transporter interaction. 
 Transporter inhibition by xenobiotics is not limited to drug-transporting proteins, 
and nor are these interactions limited to a single polarized epithelium.  Therefore, it may 
be possible that a xenobiotic can interfere with transporter function at the mammary 
gland, resulting in an altered flux of nutrients across the mammary epithelia.   
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1.2.5.  Benefits of Breastfeeding 
 
“Human milk is species-specific, and all substitute feeding 
preparations differ markedly from it, making human milk uniquely 
superior for infant feeding”100 
 
 The unique composition of human milk has evolved from our distant past to 
encompass a plethora of critical components in addition to nutrients, such as immune 
factors and hormones, that not only make it superior for infant nutrition, but also, 
overall infant health and wellness.101, 102 
1.2.5.1.  Health Benefits 
1.2.5.1.1.  Health Benefits to Nursing Infant 
 The unique species-specific components of human milk (hormones, immune 
factors, growth factors, and micro- and macro- nutrients) that arrive in the milk either in 
part or fully attributed to the function of mammary gland transport systems, provide the 
nursing infant with critical nutrient and protective factors, which leads to numerous 
health benefits associated with infant breastfeeding. There exists a myriad of published 
literature on the possible effects of exclusive breastfeeding on protection from acute and 
chronic illnesses, and its role in infant growth and development7, 103-108.  Therefore the 
following section will only provide a small insight into the proposed claims that 
breastfeeding is protective and critical for optimal infant development. 
1.2.5.1.1.1.  Acute Disease 
 Acute infant diseases are often associated with the development of colic in 
newborns and can lead to serious health problems if left untreated106, 107, 109, 110.  Recent 
longitudinal analyses of data shows that as little as a 2-month increase in exclusive 
breastfeeding (6 versus 4 months) significantly decreased the incidence of pneumonia 
and otitis media in newborns within the first year of life109, and exclusive breastfeeding 
decreases the risk of developing acute gastrointestinal infections, urinary tract infections, 
and necrotizing entercolitis in newborns by an altered mucosal colonization pattern of 
gut microflora110.  Exclusive breastfeeding has been shown to be protective against a 
host of other disorders including asthma and allergy106, 107, however the literature 
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remains divergent. 
1.2.5.1.1.2. Chronic Disease 
 The prevention of many chronic diseases such as cardiovascular disease, obesity, 
and diabetes has received a large amount of attention recently111.  The onset of many of 
these diseases has been attributed, at least in part, by early life nutritional status104, 105, 
112-115. 
 The epidemic of adolescent and adult obesity in western society is constantly 
increasing and is one of the leading contributors to the development of cardiovascular 
disease, diabetes and insulin resistance, and early life mortality111.  Recent reviews 
summarize the majority of literature and breastfeeding has shown to have a small yet 
positive effect on obesity in adult life as determined using body mass index (BMI) 
analysis108, 116, 117.  Despite the attempt to control for all confounders, many of the 
studies indicate that the uncontrollable factors such as adult diet and genetic variability 
may offset the potential positive effects. 
 Significant differences in blood lipid profiles do exist between children who are 
exclusively breastfed and those who are prematurely weaned during the first year of life.  
Exclusively breastfed infants show a significantly increased accumulation of serum 
cholesterol, higher LDL cholesterol and apoprotein B concentrations, and higher levels 
of certain HDL cholesterols during the initial months of life118.  However, meta-analyses 
following breastfed infants into later life have not been able to decisively predict the 
effect of breastfeeding on the risks of cardiovascular disease.  Marked differences visible 
in early childhood have seemed to disappear in some investigations, as serum lipid 
profile differences do not last into later life 119.  However similar meta-analyses seem to 
maintain that breastfeeding and its duration actually improve blood lipid profiles, both in 
youth120 and later adolescence and adulthood121. 
 Similarly, the causality between exclusive breastfeeding and improved blood 
pressure in adolescence and adulthood are also misleading121-125.  Longitudinal studies 
indicate a positive effect of breastfeeding on blood pressure; however, the magnitude of 
change is similar to that of a reduced salt diet114 and may be a function of adult lifestyle 
and diet habits.  On the other hand investigations question the experimental power and 
error in showing a causal relationship when controlling for all potential confounders122.  
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 Diabetes is a metabolic disorder characterized by persistent hyperglycemia 
commonly resulting from an autoimmune disorder attacking pancreatic β-cells and 
consequently an inadequate insulin secretion (type I), or a lifestyle-related disorder 
where there is an insensitivity to insulin at the target tissue, as well as inadequate β-cell 
function and insulin production (type II).  Much of the literature states that there is a 
positive dose-response relationship between breastfeeding and the incidence/risk of type 
I diabetes mellitus (DM)126-128.  For instance, a case-control study in Czech children126 
and Australian diabetes patients128 showed a protective effect of breastfeeding duration 
on the development of type I DM that was unaffected by any confounding variables.  
However, other such studies indicate that the incidence of type I DM may not be 
attributed to duration of breastfeeding or the early introduction of cow’s milk and/or 
solid foods, and may only be determined by a genetic predisposition129.  The proposed 
protective effects of breastfeeding on the incidence of type I DM are extremely 
divergent and unclear. 
 In comparison to type I DM, there is far less literature associating breastfeeding 
duration on the risk of developing type II DM in later life.  Breastfeeding does appear to 
be protective against developing type II DM130, 131; however, similar to type I DM, the 
confounding variables for developing type II DM are far too many to control and 
therefore the possible mechanisms governing the protective effects of breastfeeding on 
type II DM are also vague and unclear. 
 The potential protective effect of breastfeeding on numerous infections begs the 
question to what extent breastfeeding may protect against childhood cancers.  Meta-
analyses show that breastfeeding may be protective against certain types of childhood 
cancer such as acute childhood leukemia132, 133 and non-Hodgkin’s lymphoma134.  
Nevertheless, meta-analyses done in other countries have shown no such correlation135 
indicating that there may be location-based confounders. 
 The positive effects of breastfeeding duration on the prevention of chronic 
diseases such as cardiovascular disease, blood pressure, and diabetes may be attributed 
(at least in part) to the programming of lipid metabolism due to the higher fat content of 
breast milk compared to that of formula and hence the positive effects on later life 
obesity.  However, much experimentation is needed to determine if there exists such a 
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causal relationship. 
1.2.5.1.1.3. Growth & Development 
 Breast milk contains a plethora of essential components critical for proper 
growth and development, such as the long-chain polyunsaturated fatty acids (LC-
PUFA).  LC-PUFA are abundant in breast milk and play a key role in membrane 
structure and are used in extremely high amounts during brain and retina 
development136.  Their role in brain and retina development has indicated them as 
primary players in proper overall infant growth and development. 
 Exclusively breastfed infants are significantly heavier and longer (length-for-
age) than partially-breastfed or formula fed infants throughout the first 3 months life.  
However, this difference declined thereafter and by 12 months where weight and length 
were similar, independent of early life nutrition137.  Also in premature infants, 
breastfeeding contributed to higher motor skill development at 3 and 12 months and 
higher cognitive scores at 12 months compared to formula fed infants at the same age138.  
Does breastfeeding only increase cognitive function in premature infants?  In a 
retrospective study of Danish men and women, it was shown that breastfeeding did 
increase intelligence in adult life139; however, it appears that the results of many of these 
studies need to be critically evaluated before proper interpretation can occur.  A recent 
review describes that in a sample of 40 publications between 1929 and 2001, only 2 
publications met the proper standards of high-quality feeding data, and of those 2 studies 
the results were divergent140.  Therefore, although results appear promising, they may 
also be misleading. 
 It has been well documented that exclusive breastfeeding has the possibility to 
protect against a myriad of childhood illnesses and diseases such as gastrointestinal tract 
infection/diarrhea, otitis media, upper respiratory tract infections, obesity, cardiovascular 
disease, diabetes, and certain cancers.  However, such benefits may not necessarily 
represent our society on an individual level because the majority of studies are 
longitudinal in nature.  These studies lack an exclusive causal relationship (due to 
numerous confounding factors) between individual breastfeeding practices/durations and 
health benefits.  Nevertheless, the possible role that breastfeeding may play on 
immediate and/or future health and development status cannot be ignored. 
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1.2.5.1.2.  Health Benefits to Mother 
 Although breastfeeding is considered to be optimal for overall childhood health 
and wellness, it offers many health benefits to mothers as well.  Changes in post-partum, 
serum hormone levels, such as prolactin, oxytocin, estrogen, and progesterone have been 
shown, not only to regulate lactation status, and milk production22, but also to regulate 
many other processes, which are beneficial to the mother.  For instance, the increased 
serum concentrations of oxytocin are attributable to the increase in post-partum fat 
mobilization22 and therefore the rapid return to pre-pregnancy weight.  In addition, 
prolonged breastfeeding has also been suggested to protect against certain cancers such 
as pre-menopausal, but not post-menopausal breast cancer141, with mechanisms 
unknown. 
1.2.5.2.  Social Benefits 
 In addition to the immediate and long-term health benefits of breastfeeding to 
both the mother and the nursing infant, both parties also benefit from the close, social 
interaction during breastfeeding.  The long periods of maternal care allow the passage of 
maternal influences onto the nursing young.  This “privileged” interaction between 
mother and nursing infant provides a feeling of safety, comfort, and well being for both 
mother and infant2, 142.  For mothers suffering from post-partum depression, 
breastfeeding allows them to focus on a very positive experience, and the increase in 
maternal oxytocin levels during this time can help reduce the effects of depression143.  
Furthermore, the close skin-to-skin interaction (also known as “kangaroo care”144) 
between mother and infant has been shown to be analgesic.  Infants exposed to a heel-
lance, a routinely used hospital procedure to collect blood, showed a major decrease in 
pain response by upwards of 91% as indicated by outcome measure of crying and 
grimacing145, 146.  This study also showed that both resting and stressed heart rates were 
reduced, confirming a possible analgesic role of breastfeeding for the nursing infant.  In 
addition, the close skin-to-skin contact between mother and infant has been shown to be 
a good mediator of infant body temperature147.  This skin-to-skin contact may 
subconsciously increase the awareness of the infant to mother and visa versa and may 
ultimately help to stimulate breastfeeding in couples experiencing breastfeeding 
difficulties147. 
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1.2.5.3.  Economic Benefits 
 The ability of women to breastfeed represents a significant economic benefit to 
both the private and public sectors of health care and economy.  If breast milk is 
considered a food commodity and therefore a product that contributes to the total food 
supply (gross domestic product (GDP)), breastfeeding demonstrated a net economic 
benefit of $2.2 billion/year in Australia alone148.  Such an economic benefit should prove 
to be extremely beneficial to the economy of any nation.  However, even if breast milk 
is not considered as a food commodity, it still holds many benefits.  The ever-rising cost 
of infant formula puts a real strain on those mothers who do not breastfeed by choice or 
by advice of a physician, specifically low-income and younger mothers who are unable 
to invest extra resources into specialized infant formulas. 
 The positive health benefits associated with breastfeeding such as the decreased 
risk and severity of childhood illnesses reflects a decreased stress to the personal and 
public health care system by lowering the incidence of visits to pediatric physicians and 
hospital stays.  During the first year of life, there were 2033 additional office visits, 212 
additional hospitals stays and 609 additional prescriptions written for each 1000 never 
breastfed infants when compared to infants who were exclusively breastfed for only 3 
months149.  The additional health care services for non-breastfed infants cost the health 
care system between $331 and $475 per never-breastfed infant during the first year of 
life in the United States149. 
1.2.5.4.  Endorsement & Promotion of Breastfeeding 
 Recently, an increased effort to promote and endorse breastfeeding has occurred 
due to the health, social, and economic benefits of breastfeeding. Many governing 
agencies (U.S. Food and Drug Administration, Public Health Agency of Canada, 
Canadian Pharmacists Association, American Academy of Pediatrics, World Health 
Organization) publish yearly position statements on the promotion of breastfeeding 
practices and the use of human milk in infant feeding8-12.  These statements cover all 
major areas including feeding frequency and duration of feeding practices, pacifier use, 
proper feeding positions, and contraindications to breastfeeding.  Despite the small 
discrepancies in the messages of various supporting groups, they each independently and 
collectively support exclusive breastfeeding for at least 4-6 months, and the continuation 
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of breastfeeding with the addition of solid foods lasting up to 1-2 years of age. 
 National initiation and duration rates are on the rise.  Breastfeeding has been 
constantly promoted since the mid 1960’s, when it was determined that human milk was 
far superior to artificial formulations.  Recent reports from Abbott Laboratories suggest 
that the initiation of breastfeeding in 2001 reached an all-time high in the United States 
with ~70% of all mothers were exclusively breastfeeding in the early post-partum 
period.  However, by 6 months post-partum, only ~30% of mothers were still 
exclusively breastfeeding150.  Similar trends exist in Canada with initiation rates in 
Ontario in 2001 accounting for ~80% - 90% of all mothers at the time of departure from 
hospital, which decreased by ~25% by 4 weeks after discharge with those mothers 
switching to formula151.  The percentage of mothers who initiate breastfeeding in the 
early post-partum period meets the benchmark expectations from the governing 
agencies; however, the duration of breastfeeding falls far below these expectations. 
 
1.2.6.  Risks of Breastfeeding with Exogenous Drug Exposures 
 Few situations exist where breastfeeding is contraindicated for infant health. 
Concerns arise though in the presence of maternal exposure to drugs.  The two critical 
risks associated with intentional (drugs) or unintentional (environmental toxins) 
maternal exposures are milk levels of drugs/xenobiotics and the possibility of these 
exposures affecting mammary gland functions, such as altered hormone regulation, milk 
production, and milk composition. 
1.2.6.1.  Safety Evaluation for Drug Use in Pregnancy & Lactation 
  Many healthcare practitioners still rely solely on reports from the American 
Academy of Pediatrics (AAP) and from a select group of researchers8-14 to dictate the 
safety of breastfeeding practices with maternal medication use.  These reports are based 
primarily on the appearance of parent drug in maternal milk and consequential neonatal 
exposure levels (exposure index). In some cases, safety recommendations are based on 
known, adverse effects on milk production.  In 2002, the FDA sponsored a workshop 
mandated to provide information on the transfer of drugs into milk152.  The primary 
findings from this meeting were that the following 3 items must be sufficiently evaluated 
in order to deem a drug safe for use in breastfeeding:  maternal clearance (where an 
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increase in maternal clearance decreases neonatal exposure), neonatal clearance (where a 
decrease in neonatal clearance increases the exposure), and the possibility of active 
metabolites of parent compounds eliciting a response.  None of these objectives attempt 
to characterize the ability of exogenous xenobiotics to influence the maternal milk 
composition, most notably because the function of transporters at the mammary gland 
has been, and continues to be, largely overlooked. 
1.2.6.2.  Drug Transfer into Maternal Milk  
 All compounds are present in human milk.  The majority of drugs present in 
human milk arrive due to their physicochemical characteristics as they find passive 
equilibrium between maternal plasma and milk153, 154.  Passive mechanisms, although 
being the most predominant mechanism of drug entry/exit from maternal milk, are not 
the exclusive mechanism to which chemical entities can transverse the polarized 
mammary epithelium.  Milk-to-serum ratios have been observed at levels as high as 30 
indicating that there are other mechanisms, such as active mechanisms present to 
transport drugs into maternal milk155.  The precedence for the active transport of 
compounds into breast milk by transporters was recently established with the breast 
cancer resistance protein (BCRP), which is upregulated during lactation and actively 
accumulated toxicologically important substrates into the breastmilk156.  Components of 
the active transport of xenobiotics into breast milk may also include constitutively 
expressed proteins from both the ABC and SLC families of transporters at the mammary 
epithelia, which include various nutrient transporters3, 4.   
Despite the specific nutrient-substrate profile of the nutrient transporters, some of 
these transporters also serve to transport many clinically relevant xenobiotics, some of 
which are not contraindicated during pregnancy and/or lactation9-11.  Members of the 
organic cation/carnitine transporter family (OCT, OCTN), concentrative nucleoside 
transporter family (CNT), and equilibrative nucleoside transporter family (ENT) 
although specific for organic cations, organic cations/carnitine and nucleosides, 
respectively, they also serve to transport clinically relevant xenobiotics such as 
anticonvulsants, β-lactam antibiotics157-160, acyclovir (ACV), gancyclovir (GCV) and 
zidovudine (AZT)155, 161.  It may be possible that many other nutrient transporters have a 
substrate profile that encompasses other clinically relevant drugs. 
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1.2.6.3.  Xenobiotic-Nutrient Transporter Interactions 
 It has been established that these “nutrient-specific” transporters also transport 
clinically relevant xenobiotics in addition to their nutrient substrates, so what happens 
when breastfeeding is initiated with an intentional or unintentional xenobiotic onboard?  
It is possible that the xenobiotic can out compete the nutrient substrate for the active site 
increasing the uptake of the xenobiotic, a phenomenon that is just recently being 
investigated with respect to one of the many mammary gland transporter families, the 
organic cation/carnitine transporter family162.  However, this investigation and any 
others like it, only focus attention on the active transport of the xenobiotic into milk and 
consequent neonatal exposure to the unwanted compound.  Little attention is being 
directed towards the possibility of this interaction altering the nutrient profile of 
maternal milk, specifically, the critical micronutrient composition of maternal milk 
where small alterations in these critical components may lead to long term metabolic 
regulation/programming. 
 
1.2.7.  Methods to Assess Transporter Expression, Function, & Interactions 
 It is becoming increasingly more important to fully understand the functions of 
transporters expressed at the lactating mammary gland to give insights into both 
mammary gland function/regulation and as a possible screening tool in predicting the 
ability of xenobiotics to influence the functions of these transporters.  The use of in vitro 
cell culture model systems as an alternative to animal experimentation in basic science 
research has recently received much more attention as a possible screening tool for 
xenobiotic uptake and metabolism studies163-166.  In vitro model systems are far more 
cost effective, have higher throughput, allow for greater replicates (stronger statistical 
power), and they add simplicity and accessibility to the study, both of which are difficult 
to achieve with the complexity of in vivo animal systems.   
Furthermore, the rat mammary gland shows remarkable similarities with 
mammary glands of human population with regards to mammary gland function (milk-
to-serum ratios), similar functional assessments (with respect to xenobiotic transport 
processes), and similarities in neonatal requirements (strict breast feeding until 
weaning)155.  In addition, rat models offer an animal model system that is extremely cost 
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effective and accessible, and allows for sufficient sample size that is easily manipulated 
to an extent far beyond that of other tissue sources (i.e. human3).  Therefore, the female 
rat will serve as a relevant model system for the evaluate nutrient transporters at the 
lactating mammary gland. 
1.2.7.1.  Isolated Plasma Membrane Vesicles 
 Membrane fractions isolated from whole tissue samples is a simple system for 
the evaluation of transport mechanisms.  The major advantages of this method lay in its 
simplicity compared to whole tissue counterparts, the ability to eliminate metabolism as 
a confounder, and the ability to alter the fluid composition on either side of the 
membrane167, 168.  However, these advantages are also major disadvantages when 
attempting to extrapolate results to in vivo, or even isolated, whole organ systems.  
Furthermore, membrane heterogeneity becomes a major disadvantage167 and the 
composition of gradient media can further influence vesicle yeild169.  Therefore, these 
systems are primarily used to obtain information regarding the affinity (Km) and capacity 
(Vmax) of various transporters167, 168, much of which has been largely established with 
respect to secondary-active, nutrient transport170. 
1.2.7.2.  Gene Expression Systems 
 Gene over-expression systems offer the advantage of inducing the expression of 
a specific transporter target171.  The major advantage of gene over-expression, over that 
of isolated membrane vesicles, is the ability to precisely induce the target expression 
eliminating the variability of vesicle membrane composition.  Furthermore, it allows for 
a more favorable cell condition as it maintains cellular architecture and can more 
accurately reflect the intracellular environment.  However the disadvantages of this 
system are similar in that it is difficult to extrapolate results to in vivo systems171.  
1.2.7.3.  Isolated Mammary Gland Perfusion 
 Isolated whole-organ perfusions have a main advantage in that they maintain the 
cellular architecture and in vivo environment of the organ.  In the case of the mammary 
gland, which is grounded on the interactions between the milk-producing cells and their 
extra-cellular matrix environment172-177, a whole organ perfusion would seem like a very 
reasonable system.  However, aside from the direct advantage of this technique there are 
some important disadvantages that include the possibility of specialized surgical 
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techniques, the low throughput capability, and in order to maintain physiological 
conditions, the perfusion rate must match organ blood flow178. 
1.2.7.4.  Cell Lines 
 In vitro cell culture systems have significant advantages over the complexity of 
an in vivo animal system; however, the major disadvantage to in vitro models is that the 
majority of current model systems utilize cultured cell lines as a model system, which 
may or may not be representative of the in vivo barrier.  For instance, the highly used 
Caco-2 cell line used to study numerous carrier-mediated mechanisms, showed 
markedly different transporter expression levels than the gastrointestinal barriers in 
vivo179 and therefore does not prove to be a relevant system when protein carrier-
mediated mechanisms predominate.  Therefore, any relevant in vitro model system must 
be validated using cells derived from the corresponding tissues to accurately reflect the 
in vivo barrier characteristics164.  Currently, primary cell culture systems have been 
established for the evaluation of barrier functions at the blood-brain barrer180, the blood-
retinocyte barrier181, and the blood-testis barrier182, each of which have been shown to be 
more reliable for extrapolation of in vitro findings.  Therefore a primary mammary 
epithelial cell culture would be far more reliable for the evaluation of the mammary 
gland barrier functions. 
1.2.7.5.  Total RNA Isolation From Whole Mammary Gland Tissue 
 The majority of reported literature suggests that the isolation of total RNA from a 
section of whole mammary gland tissue is an appropriate and accurate assessment tool to 
evaluate transporter expression levels31, 52, 68-71, 73.  However, the mammary gland is 
composed of a heterogeneous population of cell types including adipose cells, 
myoepithelial cells, immune cells, milk-producing epithelial cells, and fibroblasts.  A 
whole mammary gland preparation may not accurately reflect the true nature of the 
processes involved in the transport of solutes through the mammary gland epithelia into 
the breast milk, and consequently, a more relevant cell source such as a pure population 
of mammary epithelial cells would allow for far better assessments of transporter roles 
in the regulation of breast milk composition. 
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1.2.7.6.  Primary Mammary Epithelial Cell Isolation & Culture 
 Isolated mammary epithelial cells from virgin or lactating animals, using various 
techniques (flow-cytometry183, tissue digestion, or magnetic purification184) have been 
shown to develop into fully functioning alveolar-like structures after time in culture, if 
cultured appropriately on an extra-cellular matrix185-189.  Cultures of this nature prove to 
be extremely beneficial as single cells grow into these fully functioning alveoli that are 
composed of a near pure population of milk-producing cells.  Such characteristics 
facilitate the investigation into mechanisms occurring in the alveolar cells.  However, 
disadvantages of this method exist beginning with the isolation method.  Flow-
cytometry isolation requires expensive equipment that may not be accessible to all 
individuals190; magnetic separation techniques (i.e. Dynabeads®191) are expensive and 
require specific antibody-bound magnetic beads to ensure a strict population of cells; 
and tissue digestion techniques involving a single-cell suspension require the use of 
enzymes that can be extremely harmful to cells192.  In addition to the mechanical 
disadvantages, single cells must spend days in culture (10+) to develop into fully 
functional in vitro mammary gland193. 
1.2.7.7.  Primary Mammary Epithelial Organoid Isolation & Cell Culture 
 Mammary epithelial organoids (or small organs) are clumps of alveolar cells and 
are quickly isolated from lactating mammary glands using enzymatic digestion185, 194.  
Isolated MEO are composed primarily of mammary epithelial cells195, which are the 
functional cell type when assessing substrate movement across the mammary gland 
barrier.  Therefore, appropriately cultured organoids share the same advantages as a 
primary culture involving single alveolar cells.  However, organoids are isolated while 
functional and therefore are useful almost immediately after isolation.  Therefore, 
organoids isolated from female rats will allow for better evaluations of transporter 
expression in lactating mammary epithelial cells.  In addition, if MEO are appropriately 
cultured on an extra-cellular matrix in serum-free conditions, they will serve as a 
relevant in vitro system to evaluate nutrient transporter function and possible 
transporter-xenobiotic interactions. 
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1.2.8.  Perspectives 
 In the parallel relationship that exists to assess and maintain neonatal health and 
safety there exists a crucial dyad: limiting drug exposures and assuring proper nutrition.  
Evaluation of drug levels in the breast milk (a measure of infant exposure), albeit a 
reasonable predictor of neonatal exposure to drugs, does not provide any assessment of 
the possible lack-of-exposure to critical micro- and macronutrients with such putative 
drug exposures due to interactions with mammary epithelial cell function.  Therefore, 
the total assessment of neonatal safety with drug exposures MUST include the possibility 
of drug exposures altering the nutrient composition of maternal milk.  It is well 
understood that active transport of drugs across membranes results in milk-to-serum 
ratios that can reach as high as 30 thus increasing the dose received by the nursing 
infant.  Furthermore, these drug moieties are often substrates for nutrient transporters, 
and may competitively or non-competitively inhibit the transport of nutrients into 
maternal milk.  The critical question is, then, under what circumstances will maternal 
exposure to drugs or environmental toxins pose a significant nutritional risk to the 
nursing neonate by interfering with proper mammary epithelial cell function?  This 
thesis work provides an evaluation of the temporal expression patterns of various 
micronutrient transporters throughout lactation in the rat mammary gland.  Furthermore, 
this thesis work will provide an assessment of when the mammary gland may be 
susceptible to a xenobiotic attack by exogenous compounds and, in addition, lay the 
basic groundwork for an in vitro model system that will, at its full capacity, provide an 
accurate assessment tool to evaluate xenobiotic-nutrient transporter interactions.  This is 
only a small insight into a lifelong research endeavor; however, ensuring optimal breast 
milk composition is one additional measure in safeguarding overall infant health and 
wellbeing while breastfeeding. 
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- II - 
Purpose of Project 
∑ 
 
2.1.  Objectives 
2.1.1.  Objective I 
 To evaluate and characterize nutrient-transporter mRNA expression kinetics in 
whole mammary tissue and a purified population of mammary epithelial organoids 
(MEO) isolated from female Sprague-Dawley rats at various stages of pregnancy, 
lactation, and involution using quantitative real-time reverse transcription polymerase 
chain reaction (QRT-PCR).  This objective will characterize the differences in 
expression patterns and levels between the literature “gold standard” (whole mammary 
gland tissue) and a plausible, more appropriate tissue source rich in milk-producing 
epithelial cells (MEO). 
2.1.2.  Objective II 
 To determine if appropriately cultured mammary epithelial organoids (MEO) 
maintain in vivo transporter expression to lay down critical groundwork for the 
development of an in vitro screening tool assessing xenobiotic-nutrient-transporter 
interactions. 
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2.2.  Hypotheses 
2.2.1.  Objective I 
Nutrient transporter mRNA expression levels change throughout pregnancy and 
lactation in order to accommodate the nutrient composition of breast milk that serves the 
immediate needs of the developing nursing neonate.  Furthermore, transporter 
expression levels are different in a tissue sample rich in secretory cells (MEO) than in 
whole mammary gland tissue. 
2.2.1.  Objective II 
 Isolated mammary epithelial organoids (MEO) cultured in an environment rich 
in extra-cellular matrix proteins (Matrigel™) maintain transporter expression at the 
mRNA level to serve as an appropriate system to evaluate xenobiotic-transporter 
interactions at the mammary gland. 
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- III - 
Materials & Methods 
∑ 
 
3.1.  Materials 
Collagenase type III was purchased from Cedarlane Labs (Hornby, Ontario, 
Canada).  Dispase type II, sterile saline (0.9%), fetal bovine serum (FBS), sterile 15 mL 
and 50 mL polypropylene centrifugation tubes, Falcon tissue culture flasks (T-150 & T-
75), bottle-top filters (0.2 µm & 0.45 µm), and sterile polystyrene tissue culture dishes 
(100mm) were purchased from VWR (Mississauga, Ontario, Canada).  Antibiotic 
solutions (antibiotic/antimycotic solution & gentamicin), DMEM-F12 cell culture 
medium, and phosphate buffered saline (PBS) were purchased from Invitrogen 
(Burlington, Ontario, Canada).  Autoclavable Nitex filters (530 µm & 55 µm) were 
purchased from Sefar International (Ville St. Laurent, Quebec, Canada). QRT-PCR 
Smartcycler® 25 µL reaction tubes were purchased from Fisher Scientific (Nepean, 
Ontario, Canada), and 1-step Quantitect SYBR green RT-PCR kits and RNA isolation 
kits (RNeasy Midi and Mini kits) were purchased from Qiagen Inc. (Mississauga, 
Ontario, Canada). Tissue culture reagents and hormones (fatty acid-free bovine serum 
albumin (BSA), bovine insulin, human apo-transferrin, ovine prolactin, progesterone, 
hydrocortisone, ascorbic acid) were purchased from Sigma-Aldrich (Oakville, Ontario, 
Canada) and mouse EGF was purchased from Chemicon International (Temecula, CA). 
Matrigel™, Matrigel™ thick-coated cell culture dishes (35 mm), and MatriSperse™ 
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were purchased from BD Biosciences (Mississauga, Ontario, Canada).  All other 
solvents and reagents were of the highest analytical grade available. 
 
3.2.  Animals 
Female Sprague-Dawley Crl:CD BR rats (16-week virgin, or first time 
pregnant/lactating; n = 4 per group) were purchased from Charles River Canada (St. 
Constant, Quebec, Canada) and allowed at least a 3-day acclimatization period where 
they were housed in groups of 4 (pregnancy) or housed individually (lactation & 
involution).  Animals were maintained in a temperature and humidity controlled facility 
(22°C ± 2°C) on a 12-hour light:dark cycle (0700h – 1900h), fed standard rat chow ad 
libitum and had free access to water throughout the study.  On their respective day of 
pregnancy (gestational day 15 & 20), lactation (day 1, 3, 7, 10, 14, 18) or involution 
(24h after removal of pups), animals were deeply anesthetized using an overdose of 
isoflurane (as determined by lack of reaction to a hard toe pinch) and sacrificed by 
exsanguination and thoracic cavity opening. Abdominal mammary glands (bilateral 
abdominal, cranial inguinal, and caudal inguinal) were isolated and rapidly excised.  A 
small section was removed from the mammary tissue and stored in RNAlater™ 
(Ambion Inc., TX) until further processing while the remaining tissue was stored briefly 
in 0.9% saline containing 1000 U/mL penicillin G, and subjected to tissue digestion to 
prepare a cell suspension rich in mammary epithelial organoids (MEO).  MEO’s were 
either stored in RNAlater™ as per manufacturers instructions on storage of tissue 
culture cells until subsequent RNA isolation or appropriately cultured on Matrigel™ 
coated cell culture plates.  All tissues stored in RNAlater™, were stored at -20°C until 
RNA extraction.  All procedures for the care and use of the animals were in accordance 
with CCAC regulations and approved by the University Committee on Animal Care and 
Supply (University of Saskatchewan, Saskatoon, SK, Canada). 
 
3.3.  Mammary Epithelial Organoid (MEO) Isolation 
 MEO from excised mammary glands of pregnant (gestational day 15 & 20), 
lactating (days 1, 3, 7, 10, 14, 18), and postlactational (24h after removal of pups) 
female rats were prepared as per the method of Darcey et al.185 with minor modifications 
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(Figure 3.1).  Isolated MEO using this method have been optimized and shown to 
produce a tissue source enriched with milk producing, mammary epithelial cells185, 194, 
195. 
 
 
FIGURE 3.1 – Schematic representation of mammary epithelial organoid (MEO) isolation 
from excised whole mammary glands from a female Spraque-Dawley rat.  MEO were 
isolated as per the method of Darcy et al.185 with minor modifications.  Refer to text for 
details. 
 
 Excised mammary glands were removed and stored in 0.9% saline containing 
1000 U/mL penicillin G (Table 3.1), until all tissue fragments were collected.  The 
collected mammary gland tissue was mechanically minced using sterile surgical scissors 
into uniform pieces (~1-3 mm3) in a small volume of digestion media (~15 mL; Table 
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3.1) in a sterile 30 mL beaker.  The fragments were incubated in digestion solution (10 
mL digestion media/g mammary tissue wet weight) with minimal agitation at 37°C in a 
humidified CO2 incubator for ~ 5 h (or until the majority of tissue had settled to the 
bottom of the flask as sand-like particles; MEO).  The digestion solution and resulting 
MEO were split into sterile 50 mL polypropylene centrifuge tubes and pelleted by a 10 
min 500 × g centrifugation at 4°C. The resulting pellet was washed once with 10 mL 
DMEM-F12 (Table 3.1), resuspended in 40 mL DMEM-F12, and filtered through a 530-
µm Nitex filter to allow for the passage of MEO and single cells, and the removal of 
blood vessels and large tissue fragments. 
 The filtrate was filtered once more through a 55 µM Nitex filters to allow 
passage of single cells and the retention of MEO.  MEO retained on the filter were 
rinsed off into a sterile tissue culture dish using a small volume of adherence media 
(Table 3.1) and transferred to a sterile T-75 tissue culture flask.  The collected MEO 
were incubated at 37°C for ~ 3-4h with occasional gentle swirling to allow for remaining 
stromal contaminants and adiposities to adhere selectively to the flask.  Nonadherent 
MEO recovered after incubation were transferred to a sterile 50 mL polypropylene 
centrifuge tube and pelleted by a 10 min 500 × g centrifugation at 4°C.  The MEO pellet 
was washed once in 10 mL PBS, and resuspended in PBS:RNAlater™ (1:9) as per 
manufacturers instructions and stored at -20°C to eliminate any possible RNA 
degradation until subsequent RNA extraction. 
 
TABLE 3.1 – Detailed preparation instructions for solutions used in the isolation and 
culture of mammary epithelial organoids (MEO) from whole mammary gland tissue.  
Adapted from Darcy et al.185 
 
Solution Preparation 
Storage 
Conditions 
Primary Culture 
Medium 
See Table 3.4 
 
Prepared 
Fresh 
  
 
 
Continued… 
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… Table 3.1 continued  
Phenol Red-Free 
DMEM-F12 Medium 
Supplement phenol red-free DMEM-F12 
medium with 1.2 g/L sodium bicarbonate.  
Sterilize through 0.2 µm filter. 
4°C 
Saline Solution with 
antibiotic 
Supplement 1 L of sterile 0.9% NaCl with 
106 Units penicillin G 
4°C 
Digestion Solution Phenol red-free DMEM-F12 medium 
supplemented with 0.2% (w/v) collagenase 
III, 0.2% (w/v) dispase II, 5% (v/v) FBS, and 
50µg/mL gentamicin.  Sterilize through 
0.45µm filter. 
Prepared 
Fresh 
Adherence Medium Phenol red-free DMEM-F12 medium 
supplemented with 5% (v/v) FBS, and 50 
µg/mL gentamicin. Sterilize through 0.2 µm 
filter. 
Prepared 
Fresh 
Cryopreservation 
Medium 
Phenol red-free DMEM-F12 medium 
supplemented with 50% (v/v) FBS, 10% (v/v) 
dimethyl sulfoxide (DMSO), and 50 µg/mL 
gentamicin.  Sterilize through 0.2 µm filter 
before adding DMSO. 
-20°C 
Citric Acid Solution 0.1M citric acid in ddH2O. Sterilize through 
0.45 µm filter. 
4°C 
Nuclei Preparation 
Buffer 
20 mM Tris (pH 7.4 at 4°C) with 3 mM 
CaCl2, 2 mM MgCl, and 0.3% (v/v) Nonidet-
P40. Sterilize through 0.2 µm filter before 
adding detergent. 
4°C 
Trypan Blue Solution 0.25% (w/v) trypan blue in ddH2O. Sterilize 
through 0.2 µm filter. 
4°C 
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3.4.  RNA Isolation 
Total RNA was isolated using RNeasy Midi isolation kits as per the 
manufacturer’s directions.  Tissue samples (~ 250 mg or 1 mL pooled MEO suspension) 
were homogenized in 4 mL of lysis buffer using a Polytron tissue homogenizer.  The 
homogenized suspension was centrifuged for 10 minutes at 4500 × g to remove cellular 
debris and large tissue fragments.  The resulting supernatant was removed, transferred to 
a new sterile polypropylene centrifuge tube, and 1 volume of ethanol (70% EtOH or 
100% EtOH for whole tissue and MEO, respectively) was added to precipitate total 
nucleic acids.  The sample was applied to the Midi column and cellular contaminants 
(including genomic DNA) were washed away using a series of buffers.  The purified 
RNA sample was eluted from the column using a series of elutions using RNase-free 
water (250 µL). Total RNA was quantified by measuring the absorbance of a diluted 
sample (1:100 or 1:40 for whole tissue and MEO, respectively) of RNA:RNase-free 
water at 260 nm with a UV/VIS spectrophotometer (8453E, Agilent Technologies, Palo 
Alto, CA) according to the following equation: 
 
! 
[RNA] =  40µg /mL "  A260 "Dilution Factor  [3.1] 
 
RNA purity was assessed by measuring the absorbance ratio of a diluted sample 
(1:100 or 1:40 for whole tissue and MEO respectively) of RNA:10 mM TrisCl (pH 7.5) 
at 260 nm and 280 nm.  Pure RNA has an absorbance ratio of 1.9 – 2.1.  Total RNA was 
stored at -80°C until analysis. 
 
3.5.  Quantitative Real-Time Reverse Transcription-Polymerase Chain Reaction (QRT-
PCR) 
 The relative expression of mammary epithelial transporters was determined by 
quantitative real-time reverse transcription-polymerase chain reaction (QRT-PCR) on a 
Cephied SmartCycler® platform (Cephied, Sunnyvale, CA) with the use of one-step 
Quantitect SYBR Green RT-PCR kits and reagents.  Reactions were performed in a final 
volume of 25 µL as per Table 3.2. 
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TABLE 3.2 – QRT-PCR master mix reaction components for use on the Cephied 
SmartCycler®.  Master mix provides a final concentration of 2.5 mM MgCl2.  Adapted 
from Qiagen (http://www.qiagen.com). 
 
Component Volume/Reaction Final Concentration 
2x Quantitect SYBR Green 12.5 µL 1x 
Quantitect RT Mix 0.25 µL - 
Left Primer 2 µL 1 µM 
Right Primer 2 µL 1 µM 
RNase-free Water 6.25 µL - 
Template RNA 2 µL ≤ 500 ng 
Total Volume 25 µL - 
 
 Validation and optimization of the most favorable annealing temperature, which 
resulted in the highest primer efficiency (E) was performed (Equation 3.2) using control 
tissues from adult male Sprague-Dawley rats as positive control tissues where applicable 
(Table 3.3).   
 
! 
Slope(CT ) = "1
1
logE
 [3.2] 
 
 The optimal annealing temperature produces a single specific melt peak, which is 
not identified in a negative control (a blank sample containing no RNA template).  QRT-
PCR products were verified by horizontal 2% (w/v) agarose gel electrophoresis for a 
single band at the specified amplicon size correlating to the single, specific product melt 
peak.  Primer efficiency was calculated (as per Equation 3.2) from the slope of a 3-point 
standard curve using serial dilutions of control RNA where a slope range of -2.8 to -3.5 
and consequently efficiencies of 1.8 to 2.2 were considered as optimal. The reactions 
were quantified following determination of the threshold cycle (CT; the amplification 
cycle when PCR products are first detected above baseline fluorescence) and 
fluorescence was measured from the intercalation of SYBR green dye into the double-
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stranded product after the primer elongation phase (step 4 & 5; Figure 3.2).  A non-
template negative control was incorporated into all analysis runs. 
 The QRT-PCR protocol consisted of reverse transcription (1 cycle at 50°C for 30 
minutes), PCR initial activation step (1 cycle at 95°C for 15 minutes), three-step 
thermal-cycling (50 cycles; denaturing at 94°C for 15s, annealing at 57°C-58°C for 30s, 
and extension at 72°C for 30s), and a melt curve analysis from 65°C-95°C at 0.5°C/s 
(Figure 3.2). 
  
 
FIGURE 3.2 – Quantitative real-time reverse transcription polymerase chain reaction 
(QRT-PCR) and intercalation of SYBR green into double stranded DNA during the 
elongation phase. 
 
 Quantification of targets in the unknown samples were determined by 
interpolation from a 5-point standard curve constructed from serial dilutions of the 
appropriate male control tissue (where applicable; Table 3.3) which spanned 5-orders of 
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magnitude.  All relative fluorescence results are expressed as relative fluorescence units 
normalized to total RNA196-199. 
 
3.6.  Primer Design for QRT-PCR 
 Gene cDNA sequences for each respective transporter were obtained from the 
national center for biotechnology information Genebank (NCBI; 
http://www.ncbi.nih.gov) with primer sequences designed using Primer3 software 
(http://www.broad.mit.edu/cgi-bin/primer/primer3), a web-based primer design 
program.  All primers were designed to be between 18-20 base pairs in length to 
accommodate the product size restrictions of the Cephied Smartcycler® QRT-PCR 
platform. 
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3.7.  Primary Mammary Epithelial Organoid (MEO) Cell Culture System 
 Mammary epithelial organoids were isolated from whole mammary gland tissue 
removed from female Sprague-Dawley rats at early lactation stage (day 1) and mid 
lactation stage (day 10) as described above (with minor modifications) and cultured as 
per the method of Darcy et al.185 with culture media modifications as per Debnath et 
al.193. Following the initial filtration step (through 530 µm filter), two 1 mL aliquots of 
MEO suspension were removed and transferred to sterile 15 mL polypropylene 
centrifugation tubes for nuclei isolation and quantification.  During the 4 h selective 
adherence incubation, aliquoted MEO were passed 10-15 times through a 1 mL syringe 
bearing a 22-guage needle and incubated with 7 mL of 0.1M citric acid solution (Table 
3.1) for 90 min at 37°C in a humidified CO2 incubator.  The nuclei and residual cells 
were then collected using a 10 min 2560 × g centrifugation at 4°C and the pellet 
resuspended in 1 mL of ice-cold nuclei preparation buffer (Table 3.1).  The nuclei 
suspension was then passed 10-15 times through a 3 mL syringe equipped with a 25-
guage needle to break up and remaining intact cells.  Using a hematocytometer and the 
resulting nuclei suspension, the number of nuclei present (per milliliter) was quantified 
using 10 µL of a mixture of 90 µL nuclei suspension and 10 µL trypan blue solution 
(Table 3.1).   
 Following the 4h selective adherence incubation, the nonadherent MEO 
recovered after incubation were transferred to a sterile 50 mL polypropylene centrifuge 
tube and an aliquot of MEO suspension corresponding to 1.6 × 107 cells was removed 
and placed in a sterile 15 mL polypropylene centrifuge tube.  The remaining cells were 
suspended in cryopreservation medium (Table 3.1) at a density of 2-5 ×107 cells/mL and 
stored at -80°C.  The separated aliquot was pelleted by a 10 min 500 × g centrifugation 
at 4°C and resuspended in 4 mL of primary cell culture media containing 2% Matrigel™ 
(4 × 106 cells/mL). Three milliliters of this solution (1.2 × 107 cells) was removed and 
plated on 35 mm Matrigel™ coated plates (Figure 3.3) at 37°C in a humidified CO2 
incubator for 4 days or 8 days (primary culture media was changed every 3.5-4 days of 
plating).   
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FIGURE 3.3 – Schematic illustration of the MEO plating conditions.  MEO were isolated 
from female Sprague-Dawley rats during early (day 1) and late (day 10) lactation and 
cultured in 35 mm Matrigel™-coated cell culture plates in a defined serum-free medium 
containing a 2% Matrigel™ overlay.  See text for more detailed instructions. 
 
 On the appropriate harvesting day (day 4 or day 8), MEO were harvested using a 
cell recovery solution (MatriSperse™) as per the manufacturer’s protocol.  Briefly, 
primary culture media was removed from each plate and the cells were washed 3 times 
with ice-cold PBS.  Two millilitres of cell recovery solution was placed in each dish, 
and the dish contents gently scraped into a sterile 50 mL polypropylene centrifugation 
tube, inverted a few times and left on ice for ~1.5 h (or until Matrigel™ was completely 
dissolved and cells had settled to the bottom of the tube).  The cells were collected with 
a 5 minute 250 × g centrifugation at 4°C and washed twice in ice-cold PBS.  The final 
cell pellet was subjected to RNA extraction. 
 Total RNA was isolated using RNeasy Midi isolation kits as per the 
manufacturer’s directions.  The recovered cell pellet from each dish (~ 1.2 × 107 cells) 
was homogenized in 3.5 mL of lysis buffer using a Polytron tissue homogenizer.  A 
volume (2.5⋅V1; where V1 is the initial volume of lysis buffer) of 100% ethanol was 
added to the homogenate and the sample was vigorously mixed to precipitate nucleic 
acids and proteins. The homogenate was applied to the Midi column and cellular 
contaminants (including genomic DNA) were washed away using a series of 
centrifugation steps and various buffers.  The purified RNA sample was eluted from the 
column using RNase-free water (2 × 150 µL) and quantified as described above.  Total 
RNA was stored at -80°C until analysis. 
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TABLE 3.4 – Detailed preparation instructions for primary cell culture medium for the 
plating of mammary epithelial organoids (MEO) isolated from whole mammary gland 
tissue.  Adapted from Darcy et al.185 
 
Ingredient Solvent Stock  
Conc. 
Final  
Conc. 
DMEM-F12 Liquid Reagent 1x 1x 
Fatty-acid-free BSA DMEM-F12 10 mg/mL 1 mg/mL 
Gentamicin Liquid Reagent 50 mg/mL 50 µg/mL 
Bovine insulin 0.01N HCl 10 mg/mL 10 µg/mL 
Human apo-transferrin DMEM-F12 5 mg/mL 5 µg/mL 
Ovine prolactin 0.01N NH4OH 1 mg/mL 1 µg/mL 
Progesterone 100% EtOHa 1 mg/mL 1 µg/mL 
Hydrocortisone 100% EtOHa 1 mg/mL 1 µg/mL 
Ascorbic acid DMEM-F12 0.88 mg/mL 0.88 µg/mL 
Mouse EGF Liquid Reagent 1 mg/mL 10 ng/mL 
Matrigel™ Liquid Reagent 1x 2% (v/v) 
aEtOH – ethanol 
 
3.8.  Descriptive Statistics 
 QRT-PCR data for whole mammary gland tissue is expressed as the mean ± S.D. 
of 4 independent analyses for each group. 
 Due to tissue availability, MEO tissue was pooled at the organoid stage prior to 
RNA isolation.  Therefore, QRT-PCR data for MEO is expressed as the mean of 
duplicate analyses of pooled MEO (n = 4/group) tissue and data will give no 
representation of standard deviation. 
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- IV - 
Results 
∑ 
 
4.1.  Nutrient-Transporter mRNA Temporal Expression Kinetics 
4.1.1.  mRNA Expression Kinetics of Potential “Housekeeping Gene” Candidates 
Beta-Actin & Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH)  
 To normalize transporter mRNA expression levels, the mRNA expression levels 
of two housekeeping genes, β-actin and GAPDH, were assessed in all stages of 
gestation, lactation and involution evaluated for the transporters. Figure 4.1 and 4.2 
indicate that mRNA expression levels of both housekeeping genes do not remain 
constant with stage of mammary gland differentiation, although GAPDH tends to show 
more consistent expression than β-actin.  
β-Actin Expression in Whole Mammary Gland Tissue 
 The message encoding β-actin in whole mammary tissue is relatively stable from 
gestation stages into the onset of lactation. However from mid lactation and for the 
remainder of the lactation period β-actin decreases in expression levels to less than 20% 
of levels seen at day 15 of gestation.  With involution mRNA levels increase to exceed 
those seen in gestation (G15) by ~40% (Figure 4.1). 
β-Actin Expression in Mammary Epithelial Organoids 
 β-actin expression in MEO is higher than levels in whole mammary gland tissue 
preparations and follows a slightly different temporal expression pattern from the whole 
tissue.  β-actin expression decreases markedly from virgin by ~62% and ~70% at days 
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15 and 20 of gestation, respectively. Expression levels increase during early lactation, 
although they remain much lower than virgin levels (~55% of virgin levels).  β-Actin 
mRNA levels steadily decline through lactation with reductions of ~18%, ~50%, and 
~74% at days 3, 7, and 10 of lactation, respectively, relative to lactation day 1. By day 
18 of lactation, mRNA levels of β-actin are <10% of lactation day 1 expression levels.  
At involution, mRNA levels slightly recover to ~50% of the levels seen at day 1 of 
lactation (Figure 4.1). 
 
  
FIGURE 4.1 - mRNA expression analysis of β-actin in whole mammary tissue (Whole, 
open bars) and isolated mammary epithelial organoids (MEO, closed bars).  Total 
mRNA was isolated from whole mammary tissue and isolated mammary epithelial 
organoids from virgin female Sprague-Dawley rats and dams at various stages of 
gestation (G15, G20), lactation (L1, L3, L7, L10, L14, L18), and involution (I1).  Whole 
tissue and MEO data is expressed as relative fluorescence units (RFU) normalized to 
total RNA (ng) where whole tissue results are expressed as mean ± S.D. (n = 4/group) 
and MEO results are expressed as the mean of duplicate pooled MEO samples (n = 1; 4 
individual samples, pooled and analyzed in duplicate). 
 
GAPDH Protein Expression in Mammary Epithelial Organoids 
 GAPDH was evaluated only in MEO.  (A consistent expression of GAPDH in 
MEO would have warranted further investigation into its expression in a whole tissue 
preparation.)  GAPDH mRNA expression in MEO drops markedly from virgin levels by 
day 15 and 20 of gestation by ~70% and ~85%, respectively.  GADPH mRNA increases 
by ~85% and ~110% at day 3 and day 7 of lactation, respectively, but decline thereafter 
reaching levels that are ~50% higher than lactation day 1 expression values.  Involution 
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mRNA levels increase to reach ~50% of the expression levels seen in the virgin tissues 
(Figure 4.2). 
 
FIGURE 4.2 - mRNA expression analysis of GAPDH in isolated mammary epithelial 
organoids (MEO).  Total mRNA was isolated from isolated mammary epithelial 
organoids from virgin female Sprague-Dawley rats and dams at various stages of 
gestation (G15, G20), lactation (L1, L3, L7, L10, L14, L18), and involution (I1). Data is 
expressed as relative fluorescence units (RFU) normalized to total RNA (ng) where 
MEO results are expressed as the mean of duplicate pooled MEO samples (n = 1; 4 
individual samples, pooled and analyzed in duplicate). 
 
4.1.2.  mRNA Expression Kinetics of ATP-Binding Cassette Transporter Super Family 
Throughout Pregnancy & Lactation 
4.1.2.1.  The Multi-Drug Resistance Proteins (Mdr; P-Glycoprotein) 
Mdr Protein Expression in Whole Mammary Gland Tissue 
 Mdr1a mRNA expression levels in whole mammary tissue is markedly reduced 
throughout pregnancy and the whole lactation period.  mRNA levels of Mdr1a at the 
onset of lactation drop to reach levels less than 25% of the levels seen at day 15 of 
gestation, with further reductions to <10% for the remainder of lactation. mRNA 
expression levels begin to recover with early involution(~80% of those seen at the onset 
of lactation) (Figure 4.3A). 
 Mdr1b expression is nearly diminished with the onset of lactogenesis with levels 
throughout the entire lactation period expressed at less than 5% of the expression level 
seen at day 15 of gestation.  Similar to Mdr1a, Mdr1b levels at involution recover 
slightly and reach levels similar to those seen at day 20 of gestation (Figure 4.3B). 
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Mdr Protein Expression in Mammary Epithelial Organoids 
 Although Mdr1a and Mdr1b mRNA expression levels in MEO is markedly 
higher than whole tissue preparations, the pattern of expression is similar.  Mdr1a 
mRNA levels drop ~68% and ~72% from the quiescent state (i.e. virgin) by day 15 and 
day 20 of gestation, respectively.  These levels continue to decrease into early stage 
lactation (day 1) with mRNA expression levels reduced to ~10% of that seen in virgin 
tissues.  Despite a slight recovery by day 7 lactation (+ 177% relative to day 1 lactation), 
the mRNA levels of Mdr1a remain low for the remainder of the lactation period (> 90% 
reduction relative to virgin).  These levels show another small recovery with the onset of 
involution with mRNA levels increasing 9% relative to day 1 of lactation (Figure 4.3A). 
 Mdr1b expression levels and pattern are highly similar to those of Mdr1a 
throughout the lactation period and involution.  mRNA expression levels for Mdr1b 
drop during pregnancy reaching levels equivalent to ~45% and 35% of the expression 
seen in the quiescent state and these levels continue to drop with the onset of lactation, 
where early stages of lactation are also markedly lower than those levels seen in virgin 
tissues (< 15% of the expression seen in virgin at lactation day 1 and 3).  Mid-stage and 
late-stage lactation reflect a similar trend of decreasing mRNA expression levels.  
Despite a minor recovery of mRNA levels at day 7 of lactation, both mid- and late-stage 
lactation levels are less than 10% of those levels seen in the virgin animals.  With 
involution mRNA levels increase to levels seen in early lactation stages (~ 15% of the 
virgin level; Figure 4.3B). 
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FIGURE 4.3 - mRNA expression analysis of the multi-drug resistance proteins, Mdr1a 
(A) and Mdr1b (B), in whole mammary tissue (Whole, open bars) and isolated 
mammary epithelial organoids (MEO, shaded bars).  Total mRNA was isolated from 
whole mammary tissue and isolated mammary epithelial organoids from virgin (V) 
female Sprague-Dawley rats and dams at various stages of gestation (G15, G20), 
lactation (L1, L3, L7, L10, L14, L18), and involution (I1).  Whole tissue and MEO data 
is expressed as relative fluorescence units (RFU) normalized to total RNA (ng) where 
whole tissue results are expressed as mean ± S.D. (n = 4/group) and MEO results are 
expressed as the mean of duplicate pooled MEO samples (n = 1; 4 individual samples, 
pooled and analyzed in duplicate).  MEO expression data are represented by the right y-
axis. 
 
4.1.2.2.  The Multi-Drug Resistance-Like Proteins (Mrp) 
Mrp1 Protein Expression in Whole Mammary Gland Tissue 
 Mrp1 mRNA expression remains similar during gestation and day 1 of lactation, 
however begin to drop thereafter and reach levels at mid lactation less than 25% of those 
seen at lactation day 1. Levels remain constant for the remainder of the lactation period.  
Involution results in enhanced mRNA expression to levels ~80% of those seen during 
gestation (Figure 4.4). 
A 
B 
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Mrp1 Protein Expression in Mammary Epithelial Organoids 
 Mrp1 mRNA expression in MEO is similar in magnitude and temporal 
expression pattern to those seen in whole mammary tissue preparations.  Mrp1 levels in 
MEO decrease by ~60% at day 15 of gestation relative to virgin, which was further 
reduced to ~30% of that seen in virgin tissues by day 20 of gestation.  During early 
lactation, mRNA levels remained relatively constant (~ 30% of virgin values) until mid-
lactation where expression levels were reduced to less than 10% of that seen in virgin, 
and continued to decline until involution.  The onset of involution showed a marked 
recovery from later stage lactation (day 18) as expression levels rose to similar levels 
seen in the early stages of lactation (~ 30% of those seen in virgin tissues; Figure 4.4). 
 
 
FIGURE 4.4 - mRNA expression analysis of the multi-drug resistance-like protein, 
Mrp1, in whole mammary tissue (Whole, open bars) and isolated mammary epithelial 
organoids (MEO, shaded bars).  Total mRNA was isolated from whole mammary tissue 
and isolated mammary epithelial organoids from virgin (V) female Sprague-Dawley rats 
and dams at various stages of gestation (G15, G20), lactation (L1, L3, L7, L10, L14, 
L18), and involution (I1).  Whole tissue and MEO data is expressed as relative 
fluorescence units (RFU) normalized to total RNA (ng) where whole tissue results are 
expressed as mean ± S.D. (n = 4/group) and MEO results are expressed as the mean of 
duplicate pooled MEO samples (n = 1; 4 individual samples, pooled and analyzed in 
duplicate). 
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4.1.3.  mRNA Expression Kinetics of Solute Carrier Transporter Super Family 
Throughout Pregnancy & Lactation 
4.1.3.1.  The Organic Cation Transporter Family (Oct) 
Oct1 Transport Protein Expression in Whole Mammary Gland Tissue 
 Oct1 mRNA expression remains low throughout the late stages of pregnancy and 
early lactation.  Thereafter, mRNA levels increase steadily and by day 14 of lactation 
are more than 1700% greater than those seen at lactation day 1.  Levels thereafter 
decline into involution where expression levels are similar to those seen at day 15 of 
gestation (Figure 4.5). 
Oct1 Transport Protein Expression in Mammary Epithelial Organoids (MEO) 
 The message for Oct1 in MEO is markedly higher in whole tissue preparations 
compared to isolated MEO.  Oct1 mRNA expression levels in MEO was decreased to 
~35% and ~40% of that seen in virgin tissue by day 15 and day 20 of gestation, 
respectively.  The onset of lactation was characterized by an increase in mRNA levels 
exceeding the virgin level (~35% at lactation day 1), which continued to increase and 
peak (~110% relative to virgin tissues) by mid lactation.  Late lactation showed a steady 
decline in mRNA levels which, by day 18, had reached a level similar to those seen in 
late gestation with levels of ~65%, ~50%, and ~30% of those seen in early lactation 
(day 1) for lactation days 10, 14, and 18, respectively.  With involution, mRNA levels 
returned to similar expression levels as observed in the virgin mammary gland. Despite 
the large relative changes, Oct1 in MEO is expressed at very low levels (less than 0.35 
RFU · ng RNA-1) throughout the entire lactation period (Figure 4.5). 
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FIGURE 4.5 - mRNA expression analysis of the organic cation transporter, Oct1, in 
whole mammary tissue (Whole, open bars) and isolated mammary epithelial organoids 
(MEO, shaded bars).  Total mRNA was isolated from whole mammary tissue and 
isolated mammary epithelial organoids from virgin (V) female Sprague-Dawley rats and 
dams at various stages of gestation (G15, G20), lactation (L1, L3, L7, L10, L14, L18), 
and involution (I1).  Whole tissue and MEO data is expressed as relative fluorescence 
units (RFU) normalized to total RNA (ng) where whole tissue results are expressed as 
mean ± S.D. (n = 4/group) and MEO results are expressed as the mean of duplicate 
pooled MEO samples (n = 1; 4 individual samples, pooled and analyzed in duplicate).  
MEO expression data are represented by the right y-axis. 
 
4.1.3.2.  Organic Cation/Carnitine Transporters (Octn) 
Octn Transport Proteins in Whole Mammary Gland Tissue 
 The organic cation/carnitine transporters 1 and 2 are the most dominantly 
expressed transporters of the Octn transporter family in gestation periods. During 
lactation, Octn1 is expressed at higher levels than Octn2.  Octn1 mRNA expression 
remains nearly constant from gestation into the initial stages of lactation. By mid 
lactation (days 3, 7, and 10) levels increase reaching levels ~300%, ~255%, and ~208% 
greater than lactation day 1, respectively.  mRNA expression in later stages of lactation 
decline to reach levels nearly equivalent to early lactation (L1).  At involution mRNA 
levels are higher than day 1 of lactation by ~270% (Figure 4.6A). 
 Octn2 mRNA levels decline steadily from late gestation throughout the lactation 
period.  Early lactation stages (L1 and L3) are marked by a decrease in mRNA levels 
from gestation by ~50% for both days.  mRNA expression continues to decline 
throughout the remainder of lactation.  By day 7, levels drop to reach ~60% of lactation 
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day 1 values and by late stage lactation and involution values less than ~25% of those 
seen at lactation day 1 was observed (Figure 4.6B). 
 mRNA levels for the third member of the Octn family, Octn3 follow a similar 
expression pattern as Octn1.  Levels drop between late gestation and early lactation (L1) 
by ~40%, and then begin to increase until mid lactation.  Message levels reach ~130%, 
~120%, and 100% of those seen in early lactation (L1) for days 3, 7, and 10 of lactation, 
respectively, and drop further into late stage lactation (L14 and L18; less than 60% of 
L1 values). (Figure 4.6C). 
Octn Transport Proteins in Mammary Epithelial Organoids (MEO) 
 The expression of Octn1 and Octn2 in MEO is similar to the expression pattern 
and levels seen in whole mammary gland preparations, however Octn3 mRNA is 
markedly different in MEO, both in expression levels and expression pattern relative to 
whole tissue preparations. 
 The Octn1 shows the highest expression of all members of the Octn family in the 
quiescent state with expression levels higher than Octn2 and Octn3 by ~950% and 
~850%, respectively.  However, while Octn1 and Octn2 show a decrease in expression 
throughout the lactation period, Octn3 shows a continual increase through most of the 
lactation period to be the most dominantly expressed member of the Octn transporter 
family during lactation (Figure 4.6). 
Relative to virgin tissues, the mRNA expression for Octn1 is markedly lower for 
all stages of gestation, lactation, and involution.  Gestation levels drop to ~6% and ~5% 
of the expression level seen in virgin tissues at day 15 and day 20 of gestation, 
respectively.  The levels continue to remain low during early lactation (days 1 and 3, < 
5% of virgin levels). A marginal recovery at lactation day 7 relative to day 1 lactation (+ 
~220%) was observed, however expression remains less than 15% of the levels seen in 
the virgin state.  Late lactation is characterized by a gradual decline in expression levels, 
which by day 18 of lactation reach levels that are less than 1% of those seen in virgin.  
Involution results in enhanced expression to levels similar to those seen in day 7 
lactation at ~15% of the expression levels seen in virgin tissues (Figure 4.6A). 
Octn2 mRNA expression levels are characterized by a steady decline from the 
virgin state throughout pregnancy with levels at day 15 and day 20 of lactation 
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reflecting a ~20% and ~40% decrease in expression from virgin, respectively.  During 
early lactation levels continue to decline to reach ~50% of those seen in virgin 
mammary gland.  Octn2 mRNA levels rapidly recover at day 3 of lactation to reach 
levels similar to those seen in virgin tissue (~ 90%) followed by a similar rate of decline 
as seen in late-stage pregnancy with values at day 7, 10, 14, and 18 of lactation 
equivalent to ~80%, ~55%, ~45%, and ~15% of the mRNA levels seen in virgin tissues.  
With involution mRNA levels increase to slightly higher levels than those seen at day 1 
of lactation (~ 11%; Figure 4.6B). 
 Octn3 levels decrease with the onset of pregnancy, with levels in mid and late 
gestation expressed at ~80% and ~30% of the levels seen in the quiescent state, 
respectively.  With the onset of lactation a consistent increase in Octn3 mRNA levels is 
observed and by mid-lactation stages (day 7 and 10) mRNA levels reach ~150% and 
~280% relative to day 1 lactation and by late-lactation stages expression is ~380% and 
~400% at day 14 and 18 of lactation relative to day 1 lactation, respectively.  With 
involution further increases in Octn3 mRNA levels are observed and reach levels greater 
than 1200% relative to day 1 lactation (Figure 4.6C). 
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FIGURE 4.6 - mRNA expression analysis of the organic cation/carnitine transporters, (A) 
Octn1, (B) Octn2, ad (C) Octn3 in whole mammary tissue (Whole, open bars) and 
isolated mammary epithelial organoids (MEO, shaded bars).  Total mRNA was isolated 
from whole mammary tissue (Whole) and isolated mammary epithelial organoids 
(MEO) from virgin female Sprague-Dawley rats and dams at various stages of gestation 
(G15, G20), lactation (L1, L3, L7, L10, L14, L18), and involution (I1).  Whole tissue 
and MEO data is expressed as relative fluorescence units (RFU) normalized to total 
RNA (ng) where whole tissue results are expressed as mean ± S.D. (n = 4/group) and 
MEO results are expressed as the mean of duplicate pooled MEO samples (n = 1; 4 
individual samples, pooled and analyzed in duplicate). 
A 
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4.1.3.3.  The Equilibrative Nucleoside Transporter Family (Ent) 
Ent Transport Protein Expression in Whole Mammary Gland Tissue 
 Equilibrative nucleoside transporters 2 and 3 are the most abundant of the Ent 
transporters during gestation periods (greater than 200% of Ent1 expression), however 
with the onset of lactation (L1 and L3), Ent2 and Ent3 values drop markedly and Ent1 
becomes the most abundantly expressed protein (greater than 240% of levels seen for 
both Ent2 and Ent3).  Late stage lactation (L10, L14, and L18) shows a recovery of Ent3 
mRNA as Ent2 levels remain low and Ent1 levels drop and Ent3 now becomes most 
abundant during late stages of lactation (greater than 240% and 460% of Ent1 and Ent2, 
respectively; Figure 4.7). 
 The message for Ent1 increased markedly during early lactation to reach levels 
greater than 220% and 165% of levels seen at day 15 of gestation for lactation day 1 and 
3, respectively.  mRNA levels then drop into mid lactation and late lactation as the 
message for days 7, 10, 14, and 18 of lactation is less than 20% of lactation day 1 levels.  
With involution mRNA levels increase to slightly higher (15%) levels than day 15 of 
gestation (Figure 4.7A). 
 Ent2 mRNA decreases steadily throughout the lactation period.  Late gestation 
levels drop by ~45% from day 15 of gestation and continue to drop into early lactation 
(L1) by an additional 10%.  For the remainder of lactation Ent2 message drop to levels 
less than 50% relative to day 1 for days 3 and 7 of lactation and to less than 20% of L1 
values for days 10, 14, and 18 of lactation.  With involution mRNA levels increase to 
reach ~50% of those seen at day 1 of lactation (Figure 4.7B). 
 Ent3 mRNA decreases from gestation into early lactation where days 1 and 3 are 
~30% of those seen at day 15 of gestation.  mRNA expression continues to decline into 
day 7 of lactation (less than 15% of G15 values), however mRNA  recovered for the 
later stages of lactation to exceed day 1 values by ~40% and ~20% for lactation days 14 
and 18, respectively.  The recovery continues into involution to reach levels greater than 
114% of the message at day 1 of lactation (Figure 4.7C).   
Ent Transport Protein Expression in Mammary Epithelial Organoids 
 The expression pattern and levels for both Ent1 and Ent2 are similar between 
MEO and whole mammary tissue preparations. However for Ent3, despite sharing some 
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similarities in expression level, the expression pattern is markedly different in MEO 
than in whole tissue preparations.  Equilibrative nucleoside transporter 1 (Ent1), the 
highest expressed member of the Ent family, is expressed at levels greater than 450% 
and 350% of the expression levels of Ent2 and Ent3 during early lactation (day 1 and 3), 
respectively.  However, mRNA levels by mid lactation and thereafter remains similar 
between all members of the Ent family (Figure 4.7). 
 Ent1 mRNA expression levels during mid-stage gestation (day 15) vary slightly 
from virgin tissue (~117% relative to the virgin state). However, by day 20 of gestation 
levels return to nearly equal those of the quiescent tissue.  Early stages of lactation 
demonstrate a marked increase in Ent1 expression with increases of nearly 500% 
relative to the virgin tissues in early lactation (~511% and ~496% at lactation day 1 and 
day 3 respectively).  There is a marked decline in mRNA expression during mid- and 
late stage lactation with levels at day 7 lactation dropping to ~38% of the levels seen at 
day 1 with a continued decline to less than 5% of day 1 levels by lactation day 18.  With 
involution mRNA levels recover and reach ~243% higher levels than those seen in the 
quiescent state (Figure 4.7A). 
 Expression of the second member of the Ent family (Ent2) is markedly reduced 
throughout all stages of gestation, lactation, and involution relative to virgin tissues.  
Mid- and late stage pregnancy show a large decrease in expression of ~78% and ~90%, 
respectively, compared to virgin tissues.  This decline in mRNA expression stays 
relatively constant throughout lactation and involution with all stages expressing mRNA 
levels less than 12% of those values seen in the virgin state (Figure 4.7B). 
 Similar to Ent2, the mRNA expression of Ent3 is markedly reduced throughout 
all stages of gestation, lactation, and involution relative to the quiescent state.  All 
mRNA expression levels throughout these stages are expressed at less than 13% of those 
values seen with virgin tissues, with levels in the late stages of lactation (day 14 and day 
18) further declining to less than 7% of virgin values (Figure 4.7C). 
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FIGURE 4.7 - mRNA expression analysis of the equilibrative nucleoside transporters; 
(A) Ent1 (B) Ent2 and (C) Ent3 in whole mammary tissue (Whole, open bars) and 
isolated mammary epithelial organoids (MEO, shaded bars).  Total mRNA was isolated 
from whole mammary tissue (Whole) and isolated mammary epithelial organoids 
(MEO) from virgin female Sprague-Dawley rats and dams at various stages of gestation 
(G15, G20), lactation (L1, L3, L7, L10, L14, L18), and involution (I1).  Whole tissue 
and MEO data is expressed as relative fluorescence units (RFU) normalized to total 
RNA  (ng) where whole tissue results are expressed as mean ± S.D. (n = 4/group) and 
MEO results are expressed as the mean of duplicate pooled MEO samples (n = 1; 4 
individual samples, pooled and analyzed in duplicate).  MEO expression data for Ent3 
are represented by the right y-axis. 
A 
B 
C 
 63 
4.1.3.4.  The Concentrative Nucleoside Transporter Family (Cnt) 
Cnt Transport Protein Expression in Whole Mammary Gland Tissue 
 Concentrative nucleoside transporter member 3 (Cnt3) is the highest expressed 
member of the Cnt family throughout all observed stages of gestation, lactation, and 
involution.  Message levels of Cnt3 exceed Cnt1 and Cnt2 mRNA by an average of 
more than 4,000-fold and 360-fold, respectively, for all stages analyzed (Figure 4.8). 
 Cnt1 mRNA drops into late pregnancy to reach levels at day 20 of gestation of 
~65% of mid pregnancy values (G15).  Early lactation shows a small increase in Cnt1 
mRNA to reach levels at day 1 and 3 of lactation slightly higher than late pregnancy 
values (~82% and ~75% of G15 levels) followed by an additional increase into mid 
lactation stages (~120% and ~127% of G15 levels).  In late lactation expression of Cnt1 
decreases to reach levels similar to early lactation stages (~99% and ~80% of L1 
expression). With involution message levels increase to exceed mid pregnancy levels by 
~14%.  Despite the fluctuation of Cnt1 mRNA, the range over which this fluctuation 
occurs is very small (5.6 – 11.2 RFU · ng RNA-1) and can be considered as negligible 
(Figure 4.8A). 
 The message for Cnt2 is increased by ~250% and ~800% from mid gestation 
(G15) to late gestation (G20) and lactation day 1, respectively.  Following the peak at 
the onset of lactation, Cnt2 mRNA levels begin to steadily decline throughout the 
remainder of the lactation period to reach levels of ~65%, ~44%, ~34%, ~26%, ~13%, 
and ~9% of lactation day 1 values at days 3, 7, 10, 14, 18 of lactation and day 1 of 
involution, respectively (Figure 4.8B). 
 Cnt3 mRNA expression exhibits a similar rate of increase into early lactation as 
Cnt2.  Levels at day 20 of gestation and day 1 of lactation are ~200% and ~875% 
greater than day 15 of gestation, respectively.  Thereafter, Cnt3 mRNA decreases 
slightly to reach ~70% of lactation day 1 values by day 3 of lactation where levels 
remain relatively constant for the remainder of the lactation period.  The message for 
Cnt3 nearly disappears with the onset of involution where it reaches levels less than 2% 
of lactation day 1 values (Figure 4.8C). 
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Cnt Transport Protein Expression in Mammary Epithelial Organoids 
 Only the second member of the Cnt family, Cnt2, shared a similar expression 
level and pattern between MEO and whole tissue preparations.  The remaining two 
members, Cnt1 and Cnt3 both showed markedly different expression levels and 
temporal expression patterns between MEO and whole mammary gland tissue.  During 
early lactation (day 1 and 3), Cnt3 is expressed at markedly higher levels than Cnt1 and 
Cnt2 exceeding them by greater than 20,000% and 5,500%, respectively.  However 
during the later stages of lactation (days 14 and 18), Cnt1 mRNA then predominates as 
levels are expressed much higher than Cnt2 and Cnt3, exceeding them by greater than 
500% and 240%, respectively (Figure 4.8). 
 Mid-stage pregnancy (day 15) showed a slight increase in Cnt1 mRNA levels 
(~28% from the virgin state), which dropped more than 60% from virgin tissues in late 
stage pregnancy (day 20).  With onset of lactation a gradual increase in mRNA levels 
was observed until day 7 of lactation where expression remained relatively constant 
ranging from ~180%-270% of the relative expression seen at day 1. The onset of 
involution caused a marked increase of Cnt1 mRNA levels, which reached levels 
~735% and ~1350% relative to those observed in virgin tissues and at day 1 lactation, 
respectively (Figure 4.8A). 
Cnt2 mRNA expression decreased ~45% from virgin tissues by day 15 of 
pregnancy where it then began a steady incline.  The mRNA expression levels increased 
to reach a value ~14% greater than virgin tissues by day 20 of pregnancy and then 
peaked at day 1 of lactation with an expression level that was ~56% greater than virgin 
levels.  Thereafter, Cnt2 levels declined ~12% by day 3 lactation and ~60% by day 7 
lactation.  Expression levels continued to steadily decline after day 7 lactation and then 
plummeted to reach less than 5% of the expression seen at the initiation of lactation.  
With involution mRNA levels increased to reach similar levels as mid-pregnancy at 
~55% of the expression level seen in the quiescent state (Figure 4.8B). 
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FIGURE 4.8 - mRNA expression analysis of the concentrative nucleoside transporters, 
(A) Cnt1 (B) Cnt2 and (C) Cnt3 in whole mammary tissue (Whole, open bars) and 
isolated mammary epithelial organoids (MEO, shaded bars).  Total mRNA was isolated 
from whole mammary tissue (Whole) and isolated mammary epithelial organoids 
(MEO) from virgin female Sprague-Dawley rats and dams at various stages of gestation 
(G15, G20), lactation (L1, L3, L7, L10, L14, L18), and involution (I1).  Whole tissue 
and MEO data is expressed as relative fluorescence units (RFU) normalized to total 
RNA (ng) where whole tissue results are expressed as mean ± S.D. (n = 4/group) and 
MEO results are expressed as the mean of duplicate pooled MEO samples (n = 1; 4 
individual samples, pooled and analyzed in duplicate).  MEO expression data for Cnt1 
and Cnt3 are represented by the right y-axis 
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 The expression of Cnt3 mRNA rose dramatically during gestation to reach 
~760% and ~795% relative to virgin levels at day 15 and day 20 of pregnancy, 
respectively.  The onset of lactation sparked a tremendous increase in mRNA 
expression, with levels increasing more than 9,000% relative to the quiescent tissue 
during early lactation (day 1 and 3).  However, by mid lactation (day 7), mRNA levels 
plummeted to ~16% lower than the levels seen in virgin tissues, and by late lactation 
Cnt3 expression remained at levels less than 1% of those seen at day 1 of lactation.  
With involution a slight recovery of mRNA levels was observed and reached ~90% of 
that seen in virgin tissues (Figure 4.8C). 
4.1.3.5.  The Nucleobase Transporter Family (Ncbt) 
Ncbt Transporter Protein Expression in Whole Mammary Gland Tissue 
 Ncbt1 was expressed at lower levels than Ncbt2. Ncbt1 mRNA expression 
decreased from gestation into lactation to reach levels ~40% lower than day 15 of 
gestation by day 1 of lactation.  Levels remained relatively constant throughout early 
and mid lactation, however the message was increased markedly during late lactation to 
reach levels at day 14 and 18 of lactation that exceeded lactation day 1 levels by ~130%, 
and ~430%, respectively.  Involution caused a decrease in Ncbt1 mRNA to levels 
similar to lactation day 1 values (Figure 4.9A). 
 The second member of the nucleobase transporter family, Ncbt2, is expressed on 
average at levels over 300-fold higher for all analyzed time points than Ncbt1. Ncbt2 
mRNA expression steadily decreased throughout pregnancy and early lactation reaching 
levels of ~12% of G15 levels by day 7 of lactation and remained relatively constant for 
the remainder of lactation (~20% of the message seen at day 1 of lactation).  With 
involution Ncbt2 mRNA expression increased and approached levels observed during 
mid gestation (Figure 4.9B). 
Ncbt Transporter Protein Expression in Mammary Epithelial Organoids 
 In MEO, Ncbt1 showed a markedly different temporal expression pattern and 
expression level than a whole tissue preparation. On the other hand Ncbt2 shared some 
similarities in expression levels between the two preparations but the relative expression 
pattern was different.  Relative to other transporters, Ncbt1 was expressed at low levels 
throughout all stages of gestation, lactation, and involution in MEO. Expression levels 
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increased during gestation to reach ~278% of virgin levels by day 15 of gestation, with a 
slight drop by day 20 of gestation to a relative value of ~150%.  Expression continued to 
increase during the early stages of lactation and remained relatively steady into day 7 of 
lactation (~270% relative to virgin). By day 10 lactation expression began to decline, 
with expression levels at day 10, 14, and 18 of lactation equivalent to ~68%, ~53%, and 
~35% of those expression levels seen at the onset of lactation (day 1).  Involution 
caused another slight recovery of Ncbt1 expression that exceeded the levels seen in 
virgin tissues by ~52% (Figure 4.9A). 
 The second member of the nucleobase transporter family (Ncbt2) was expressed 
at much higher levels than Ncbt1 (> 1000%).  Expression levels markedly decreased 
during pregnancy with levels at day 15 and 20 of gestation only ~25% and ~17% of the 
expression seen in the virgin state.  By day 1 of lactation, mRNA levels continued to 
decline representing ~9% of the expression level observed in virgin animals.  At day 3 
and day 7 of lactation mRNA levels increased ~45% and ~140% from day 1 lactation, 
respectively, to reach similar levels observed in mid-stage pregnancy.  Following 
lactation day 7, mRNA levels began to decline with levels at day 10 and 14 similar to 
those seen at the onset of lactation (~10 greater and ~5% lower than lactation day 1 
respectively) and by day 18, levels have dropped to ~35% of the levels seen at day 1 of 
lactation. Involution initiated a small recovery of mRNA levels that increased ~25% 
relative to lactation day 1 (Figure 4.9B). 
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FIGURE 4.9 - mRNA expression analysis of the nucleobase transporters, (A) Ncbt1 and 
(B) Ncbt2 in whole mammary tissue (Whole, open bars) and isolated mammary 
epithelial organoids (MEO, shaded bars).  Total mRNA was isolated from whole 
mammary tissue (Whole) and isolated mammary epithelial organoids (MEO) from 
virgin female Sprague-Dawley rats and dams at various stages of gestation (G15, G20), 
lactation (L1, L3, L7, L10, L14, L18), and involution (I1).  Whole tissue and MEO data 
is expressed as relative fluorescence units (RFU) normalized to total RNA (ng) where 
whole tissue results are expressed as mean ± S.D. (n = 4/group) and MEO results are 
expressed as the mean of duplicate pooled MEO samples (n = 1; 4 individual samples, 
pooled and analyzed in duplicate). 
 
4.1.3.6.  The Oligopeptide Transporter Family (Pept) 
Pept Transport Protein Expression in Whole Mammary Gland Tissue 
 Pept1 expression in whole mammary gland tissue is sporadic and follows no 
distinct expression pattern.  Expression remains relatively constant from gestation to the 
onset of lactation (day 1).  Pept1 mRNA then quickly increases by ~210% from day 1 to 
day 3 of lactation followed by a drastic drop of signal by mid lactation with levels at day 
7 and 10 expressed at ~18% and ~26% of lactation day 1 values respectively.  A 
A 
B 
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recovery of mRNA at day 14 of lactation (~155% of L1) is followed by another drop in 
signal at day 18 (~27% of L1).  Involution drives a spike in Pept1 mRNA to exceed 
levels seen at lactation day 1 by over 700%.  Despite the large fluctuations in 
expression, the message for Pept1 is extremely low and expressed at levels less than 3 
RFU · ng RNA-1 (Figure 4.10A). 
 The second member of the Pept family, Pept2, has more than 90-fold higher 
expression levels than Pept1 for all time periods measured. Pept2 mRNA levels decrease 
by ~30% from gestation day 15 to late stage gestation, which is followed by an 
immediate recovery at day 1 of lactation to levels similar to day 15 of gestation.  During 
early lactation Pept2 message levels drop such that day 3 and 7 of lactation are ~60% 
and ~16% of levels seen at day 1 of lactation, respectively.  Thereafter, Pept2 mRNA 
levels recover during mid and late lactation with levels at days 10, 14, and 18 of 
lactation demonstrating at ~23%, ~35%, and ~60% of lactation day 1 values, 
respectively.  With involution expression levels decrease to < 30% of day 1 values 
(Figure 4.10B). 
Pept Transport Protein Expression in Mammary Epithelial Organoids 
 The Pept transporters share certain similarities with whole tissue preparations in 
expression levels at certain stages of lactation, however the temporal expression pattern 
was markedly different between the two preparations.  Pept1 mRNA in MEO was 
expressed at much lower levels than the second member of the oligopeptide transporter 
family (Pept2).  At mid-gestational stage (day 15), mRNA levels decreased ~65% from 
virgin tissues which was quickly compensated in later-stage pregnancy (day 20) with 
marked recovery in mRNA levels that exceed those seen in the virgin animals (~150%).  
Expression once again decreased in early lactation, which by day 3 of lactation dropped 
below the low levels observed at day 15 of pregnancy (a decrease of ~75% relative to 
virgin).  At day 7 of lactation mRNA reached levels ~110% greater than day 1 of 
lactation, which was followed in later stages of lactation by a gradual decline in mRNA 
levels equivalent to ~78% and ~27% higher levels as those seen at day 1 lactation for 
days 10 and 14 of lactation, respectively, and levels at day 18 decreasing below those 
seen at day 1 by ~46%.  With involution mRNA levels increased to levels similar to 
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those seen by later-stage gestation (day 20) with levels that exceeded virgin tissues by 
~150% (Figure 4.10A). 
 Pept2 expression is considerably higher (>6000%) than Pept1 in the early stages 
of lactation, however remains similar throughout the remainder of lactation.  mRNA 
levels are greatly increased from virgin levels by day 15 and 20 of gestation exceeding 
virgin levels by ~570% and ~250 respectively.  Early lactation caused another increase 
in mRNA levels, where levels at day 1 of lactation reached their highest expression 
(greater than 1000% of the levels seen in the virgin tissues), which decreased slightly 
(~23%) into day 3 of lactation.  Mid and late lactation stages demonstrated a marked 
reduction in Pept2 mRNA levels, where all expression values for days 7, 10, 14, 18 of 
lactation, and day 1 of involution are all less than 8% of the expression seen at day 1 of 
lactation (Figure 4.10B). 
4.1.3.7.  The Methotrexate Carrier (Mtx) 
Mtx1 Transport Protein Expression in Whole Mammary Gland Tissue 
 Mtx1 mRNA in whole mammary gland tissue is upregulated from day 15 of 
gestation to reach levels ~500% greater by day 20 of pregnancy.  With the onset of 
lactation, Mtx1 mRNA levels decline such that by day 10 of lactation levels were 
similar to those seen at day 15 of gestation.  This expression remained low and constant 
for the remainder of lactation.  With involution Mtx1 mRNA reached levels similar to 
early lactation at more than 300% greater than day 15 of gestation (Figure 4.11). 
Mtx1 Transport Protein Expression in Mammary Epithelial Organoids 
 Mtx1 in MEO exhibited a markedly different temporal expression pattern in 
MEO relative to whole mammary gland preparations, however in MEO, Mtx1 mRNA 
levels are expressed at a similar magnitude to whole mammary gland tissue.  During 
pregnancy Mtx1 mRNA levels decline in MEO and by day 15 and 20 of gestation, 
levels are ~60% and ~40% of the expression seen in the virgin state, respectively.  The 
onset of lactation was characterized by a gradual increase in mRNA expression levels, 
which peaked during mid lactation (~160% increase at day 7 relative to day 1 lactation) 
exceeding those levels seen in the virgin tissues by ~30%.  In the remainder of the 
lactation period mRNA levels gradually declined to reach levels similar to day 1 
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lactation (~7% higher).  With involution mRNA levels increased markedly to exceed 
virgin levels by ~26% (Figure 4.11). 
 
FIGURE 4.10 - mRNA expression analysis of the oligopeptide transporters, (A) Pept1 
and (B) Pept2 in whole mammary tissue (Whole, open bars) and isolated mammary 
epithelial organoids (MEO, shaded bars).  Total mRNA was isolated from whole 
mammary tissue (Whole) and isolated mammary epithelial organoids (MEO) from 
virgin female Sprague-Dawley rats and dams at various stages of gestation (G15, G20), 
lactation (L1, L3, L7, L10, L14, L18), and involution (I1).  Whole tissue and MEO data 
is expressed as relative fluorescence units (RFU) normalized to total RNA (ng) where 
whole tissue results are expressed as mean ± S.D. (n = 4/group) and MEO results are 
expressed as the mean of duplicate pooled MEO samples (n = 1; 4 individual samples, 
pooled and analyzed in duplicate).  MEO expression data for Pept2 are represented by 
the right y-axis. 
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FIGURE 4.11 - mRNA expression analysis of the methotrexate carrier, Mtx1, in whole 
mammary tissue (Whole, open bars) and isolated mammary epithelial organoids (MEO, 
shaded bars).  Total mRNA was isolated from whole mammary tissue and isolated 
mammary epithelial organoids from virgin female Sprague-Dawley rats and dams at 
various stages of gestation (G15, G20), lactation (L1, L3, L7, L10, L14, L18), and 
involution (I1).  Whole tissue and MEO data is expressed as relative fluorescence units 
(RFU) normalized to total RNA (ng) where whole tissue results are expressed as mean ± 
S.D. (n = 4/group) and MEO results are expressed as the mean of duplicate pooled MEO 
samples (n = 1; 4 individual samples, pooled and analyzed in duplicate). 
 
4.1.3.8.  The Divalent Metal Transporter (Dmt) 
Dmt1 Transport Protein Expression in Whole Mammary Gland Tissue 
 The message for Dmt1 remains relatively constant from mid gestation period 
until day 3 of lactation, however, mid lactation period showed a decrease in expression 
to less than 50% of values seen during gestation and early lactation stages (L3), which 
remained constant thereafter (Figure 4.12). 
Dmt1 Transport Protein Expression in Mammary Epithelial Organoids 
 The Dmt1 transporter in MEO shared certain similarities with whole tissue 
preparations in expression level and pattern during early lactation stages, however this 
similarity breaks down in later stages of lactation.  Message levels of Dmt1 deviated 
very little from virgin tissues into day 15 lactation, however declined rapidly thereafter 
to ~55% virgin levels by day 20 of gestation.  Dmt1 transcript levels remained steady, 
thereafter, into early lactation. However, levels declined rapidly during mid- and late 
stage lactation such that at day 10, 14, and 18 day lactation, transcript levels have 
decreased by ~53%, ~72%, and ~95% relative to day 1 of lactation. mRNA expression 
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recovers at the onset of involution with an increase to ~35% of the level seen in virgin 
tissues (Figure 4.12). 
 
  
 
FIGURE 4.12 - mRNA expression analysis of the divalent metal transporter, Dmt1, in 
whole mammary tissue (Whole, open bars) and isolated mammary epithelial organoids 
(MEO, shaded bars).  Total mRNA was isolated from whole mammary tissue and 
isolated mammary epithelial organoids from virgin female Sprague-Dawley rats and 
dams at various stages of gestation (G15, G20), lactation (L1, L3, L7, L10, L14, L18), 
and involution (I1).  Whole tissue and MEO data is expressed as relative fluorescence 
units (RFU) normalized to total RNA (ng) where whole tissue results are expressed as 
mean ± S.D. (n = 4/group) and MEO results are expressed as the mean of duplicate 
pooled MEO samples (n = 1; 4 individual samples, pooled and analyzed in duplicate). 
 
4.1.4.  mRNA Expression Kinetics of the Milk Protein β-Casein 
β-Casein Protein Expression in Whole Mammary Gland Tissue 
 The message encoding the milk protein, β-casein was increased throughout 
gestation where levels at very late gestation are nearly double (~90% higher) the level 
seen at mid gestation (G15; Figure 4.13).  β-casein mRNA increased from day 1 of 
lactation by ~65% at day 3 where it began to decline to reach values ~40%, and ~10% 
greater than day 1 at days 7 and 10 of lactation, respectively.  Day 14 showed an even 
further decline in mRNA levels to reach ~75% of lactation day 1 values, which was 
followed by another fluctuation in mRNA that increases to reach ~125% of day 1 
values.  With involution β-casein mRNA decreased to levels ~77% of lactation day 1 
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values.  The interindividual variation in β-casein expression, appear to be far greater 
than any of the transport proteins analyzed. 
β-Casein Protein Expression in Mammary Epithelial Organoids 
 β-casein expression was far lower in MEO than whole mammary gland RNA 
and in addition followed a far different expression pattern at all time points analyzed.  β-
casein mRNA increased markedly with the onset of pregnancy with levels exceeding 
virgin tissue levels by more than 900% (~2800% and 928% greater than virgin at 
gestation day 15 and 20 respectively).  β-casein mRNA level continued to rise into early 
lactation where levels exceeded virgin tissues by more than 3800% by day 3 of 
lactation.  However, mRNA levels drop off immediately at mid-stage and late stage 
lactation reflecting similar levels as seen in the quiescent state.  With involution a small 
recovery of mRNA was observed to reach levels ~160% greater than virgin tissues 
(Figure 4.13). 
 
 
FIGURE 4.13 - mRNA expression analysis of the milk protein, β-casein in whole 
mammary tissue (Whole, open bars) and isolated mammary epithelial organoids (MEO, 
shaded bars).  Total mRNA was isolated from whole mammary tissue (Whole) and 
isolated mammary epithelial organoids (MEO) from virgin female Sprague-Dawley rats 
and dams at various stages of gestation (G15, G20), lactation (L1, L3, L7, L10, L14, 
L18), and involution (I1).  Whole tissue and MEO data is expressed as relative 
fluorescence units (RFU) normalized to total RNA (ng) where whole tissue results are 
expressed as mean ± S.D. (n = 4/group) and MEO results are expressed as the mean of 
duplicate pooled MEO samples (n = 1; 4 individual samples, pooled and analyzed in 
duplicate).  MEO expression data are represented by the right y-axis. 
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4.2.  Primary Mammary Epithelial Organoid (MEO) Cell Culture System 
4.2.1.  Structural Architecture of Plated Mammary Epithelial Organoids (MEO) 
 Primary MEO plated using a Matrigel™ coated cell culture plate and a 2% 
Matrigel™ overlay developed into lobular (A), multilobular (B), or lobuloductal (C) 
structures resembling structures seen in the mammary gland during lactogenesis in vivo 
(Figure 4.14).  Furthermore, cultured MEO from young differentiated MEO (L1) 
appeared to maintain structural architecture up to 4 days of culture.  However, by day 8, 
there appears to be a marked reduction in viable structures (Figure 4.15). 
  
 
 
Figure 4.14 – Light microscopic appearance of isolated mammary epithelial organoids 
(MEO) plated on a thick Matrigel™ coated cell culture dish with a 2% Matrigel™ 
overlay.  Plated MEO develop into lobular (A), multilobular (B) or lobuloductal (C) 
structures resembling active milk-producing structures seen during lactogenesis in vivo.  
MEO were isolated from a lactating female Sprague-Dawley rat at day 1 of lactation and 
shown at day 5 of culture.  The background image represents a 10× magnification, 
whereas the larger insets are merely present to emphasize the developed MEO structures 
and do not represent any quantifiable magnification. 
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Figure 4.15 – Light microscopic appearance of isolated mammary epithelial organoids 
(MEO) after a plating duration of 0, 4, and 8 days on a thick Matrigel™ coated cell 
culture dish with a 2% Matrigel™ overlay.  MEO were isolated from a lactating female 
Sprague-Dawley rat at day 1 of lactation and plated on a thick Matrigel™ coated cell 
culture dish with a 2% Matrigel™ overlay.  
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4.2.2.  Transporter mRNA Expression in a Primary Mammary Epithelial Organoids 
(MEO) Cell Culture System 
 The mRNA expression of a select assortment of transporters (Mrp1, Ent1, Cnt3, 
Octn2, Octn3, Pept2) and the milk protein β-casein in MEO were assessed for their 
ability to maintain in vivo transporter expression after time in culture (4 or 8 days) 
relative to freshly isolated MEO. 
 Mrp1 mRNA expression changed markedly throughout the plating period for 
MEO plated at both lactation day 1 and lactation day 10.  Relative to freshly isolated 
MEO from day 1 of lactation, 4 days of plating decreased Mrp1 levels by ~70%.  This 
decrease continued until day 8, where harvested MEO expressed Mrp1 mRNA at levels 
less than 15% of those seen in fresh MEO.  MEO isolated from lactation day 10 showed 
a similar trend of expression as those from day 1 of lactation.  Relative to freshly 
isolated MEO from lactation day 10, 4 days of plating decreased mRNA expression 
levels by ~55%, and by 8 days in culture Mrp1 expression in day 10 MEO was less than 
30% of the expression seen in fresh MEO (Figure 4.16A). 
 Cnt3 mRNA changed markedly for MEO plated from day 1 of lactation.  
Relative to freshly isolated MEO, 4 days in culture dropped Cnt3 mRNA levels by ~ 
95%, and by 8 days was less than 1% of the levels seen in fresh MEO.  MEO plated 
from day 10 of lactation showed a similar pattern of decline; however nowhere near the 
magnitude as early stage MEO.  After 4 days in culture, Cnt3 mRNA levels decreased ~ 
15% from freshly isolated MEO, and by 8 day of culture, mRNA levels declined further 
to reach 40% of the level seen in fresh MEO (Figure 4.16B). 
 Octn2 mRNA expression in cultured MEO from day 1 of lactation showed a 
marked increase following 4 days in culture to reach levels greater than 400% of those 
seen in fresh MEO.  By day 8 of culture levels return to a level similar to those seen in 
fresh MEO (~ 38% greater than fresh MEO).  Day 10 MEO in culture showed a similar 
yet less dramatic change in mRNA levels.  Four days in culture increased Octn2 mRNA 
levels by ~22% followed by a decline to day 8 where levels were nearly equal to fresh 
MEO (~ 1.5% greater than fresh MEO; Figure 4.16C). 
 Octn3 mRNA levels in MEO from day 1 of lactation increased throughout the 
plating period.  Day 4 of culture revealed an increase in Octn3 mRNA of ~ 82% which 
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continued to rise and by 8 days in culture the mRNA levels were beyond 600% of those 
seen in fresh MEO.  Cultured MEO from day 10 of lactation decreased slightly by day 4 
of culture (~18% decrease relative to fresh) and then recovered by culture day 8 to reach 
levels ~15% greater than fresh MEO (Figure 4.16D). 
 Ent1 mRNA expression in cultured MEO from day 1 of lactation increased 
dramatically after 4 days in culture to reach levels ~225% higher than fresh MEO.  The 
expression level by day 8 of culture decreased markedly from day 4 of culture (~90%) 
to reach levels equivalent to ~40% of the level seen in fresh MEO.  Cultured MEO from 
day 10 of lactation showed a similar pattern of expression throughout the plating period 
as MEO from day 1 of lactation, however at a much lower magnitude.  Four days in 
culture increased mRNA expression by ~160% relative to fresh MEO, followed by a 
decline of ~72% (relative to day 4 of culture) to reach levels ~ 30% lower than fresh 
MEO (Figure 4.16E). 
 Pept2 mRNA expression in MEO from day 1 of lactation increased slightly 
following 4 days of cell culture (~27% relative to fresh MEO), however declined 
thereafter to dip below fresh MEO levels by ~40% after 8 days in culture.  mRNA 
expression in cultured MEO from day 10 of lactation increased more than 380% from 
fresh MEO after 4 days in culture, which was followed by a decrease in expression at 
day 8 of culture (~65% of the expression seen in culture day 4) to reach levels 
exceeding fresh MEO by more than 220% (Figure 4.16F). 
 The message encoding the milk protein β-casein in both young (L1) and older 
(L10) differentiated MEO decreased more than 98% after 4 days in culture.  Following 8 
days of culture duration, the message in young MEO was decreased to less than 1% of 
freshly isolated MEO, and the message encoding β-casein in older MEO dropped to 
visible levels that lay below the quantification level of the assay (Figure 4.16G). 
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Figure 4.16 – mRNA expression of Mrp1 (A), Cnt3 (B), Octn2 (C), Octn3 (D), Ent1 
(E), Pept2 (F), and β-casein (G) in cultured primary mammary epithelial organoids 
(MEO) after 4 or 8 days in culture. MEO were isolated from female Sprague-Dawley 
dams at day 1 (L1; empty bars) and day 10 (L10; shaded bars) of lactation and plated on 
35mm Matrigel™ coated cell culture plates with a 2% Matrigel™ overlay.  Total RNA 
was isolated after 4 days or 8 days in culture where MEO data is expressed as relative 
fluorescence units (RFU) normalized to total RNA (ng) as the mean of duplicate MEO 
samples (n = 1/group). * β-casein expression dropped below quantifiable levels by day 8 
of culture in L10 organoids. 
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- V - 
Discussion 
∑ 
 
his thesis work is the first to evaluate the mRNA temporal expression kinetics 
of 20 different transporters (3 xenobiotic transporters and 17 nutrient 
transporters) from 10 separate transporter families throughout the lactation 
period in whole mammary gland tissue and isolated populations of milk-secreting 
epithelial cells.  Characterization of mRNA levels of nutrient transporter genes in the 
lactating mammary gland may provide insight into the major proteins involved in the 
accumulation of nutrients in the breast milk.  More specifically, the expression patterns 
of transporter genes throughout lactation may identify the critical windows of nutrient 
delivery to the neonate during the suckling period.  Knowledge of transporter gene 
expression throughout lactation is a necessary first step in identifying the pivotal role of 
active transport proteins in the transepithelial movement of nutrients across the lactating 
mammary epithelia. Furthermore, it allows the identification of when xenobiotic-
nutrient transporter interactions may have the greatest impact on milk composition 
during lactation.   
 Major findings from this thesis demonstrate a complex pattern of gene 
expression in the mammary gland throughout lactation to provide adequate nutritional 
stimuli to the suckling infant.  This gene expression differed markedly between whole 
tissue preparations and isolated milk-secreting epithelial cells for β-actin, Mdr1a, 
Mdr1b, Oct1, Octn3, Ent3, Cnt1, Cnt3, Ncbt1, Pept2, Mtx1, and β-casein.  This brings 
T 
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into question whether whole mammary gland tissue is truly appropriate for an 
understanding of transporter expression in the mammary epithelium.  Since the MEO 
more accurately represents the physiological barrier between the maternal and neonatal 
system, the gene expression in MEO may better represent the transfer of nutrients across 
the blood-mammary gland barrier.  Furthermore, MEO cultured in an extracellular 
matrix-rich environment maintained transporter expression at the mRNA level, 
emphasizing the potential of a primary MEO in vitro model system to screen possible 
xenobiotic-transporter interactions at the lactating mammary gland. 
 
5.1.  Transporter mRNA Expression Kinetics in Whole Mammary Tissue Versus Isolated 
Mammary Epithelial Organoids (MEO) 
 To determine the changes in transporter expression during different stages of 
mammary gland differentiation and lactation, I used real-time QRT-PCR analysis on 
whole mammary gland tissue and isolated mammary epithelial organoids (MEO). Both 
preparations were assessed since the literature only reports transporter expression from 
whole mammary gland preparations31, 52, 71, 73.  Yet MEO preparations contain 
principally mammary epithelial cells, which are the relevant cell type when considering 
solute transport across the blood-mammary gland-barrier. Consistent with the 
hypothesis, the temporal mRNA expression patterns and levels of transporters from the 
ATP-binding cassette (ABC) and the solute carrier (SLC) family exhibit important 
differences between whole mammary gland tissue and isolated milk-producing cells 
(MEO).  Similar temporal expression patterns and relative expression levels between 
whole tissue and MEO do exist for Mrp1, Octn1, Octn2, Ent1, Ent2, Cnt2, Ncbt2, and 
Dmt1 (Figures 4.4, 4.6A, 4.6B, 4.7A, 4.7B, 4.8B, 4.9B, & 4.12, respectively). However, 
the remaining transporters/proteins show either a similar temporal pattern with markedly 
differing relative expression levels (Mdr1a, Mdr1b; Figure 4.3), or markedly different 
temporal patterns and relative expression levels (β-actin, Oct1, Octn3, Ent3, Cnt1, Cnt3, 
Ncbt1, Pept1, Pept2, Mtx1, β-casein) (Figures 4.1, 4.5, 4.6C, 4.7C, 4.8A, 4.8C, 4.9A, 
4.10, 4.11,  & 4.13 respectively).  Such discrepancies beg the question as to which of 
these two preparations, whole mammary gland or MEO, most accurately reflects the 
functional capacity of the mammary epithelium in vivo.  Since the whole mammary 
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gland is composed of a heterogeneous population of cells (adipose cells, myoepithelial 
cells, immune cells, milk-producing epithelial cells, fibroblasts), it may not accurately 
represent the true nature of the transport processes within the mammary epithelium.  
Unfortunately, no studies to date discriminate between various mammary gland 
preparations. Interestingly, similar discrepancies have been evaluated for various 
transporter mRNA levels in the testis of male Sprague-Dawley rats.  Isolated Sertoli 
cells showed a higher expression of transporter mRNA for Mdr2, Mrp1, Mrp4, Mrp6, 
Mrp7, Mrp8, Tst1, Tst2, Oatp2, Oatp12, Oct3, Octn2, Dmt1, Wilsons, Znt1, Ent1, and 
Ent2 than did a crude testis tissue extract208.  On the other hand, Sertoli cells and whole 
testis extracts show a similar level of expression for numerous other transporters 
(Mdr1a, b; Mrp2, 3, 5; Bsep; Ntcp; Ibat; AbcG5, G8; Oatp1, 3, 4, 5, 9; Pgt,; Oat1, 2, 3, 
k; Oct1, 2; Octn1; Menkes; Cnt1, 2; & Pept1, 2).  These results support the expression 
data of the current study where a tissue source composed of a heterogeneous population 
of cells types may exhibit important differences in transporter expression when 
compared to isolated cell populations, depending on the localization of these proteins 
(i.e. barrier epithelium or ubiquitously expressed).  In the current study isolated MEO 
show a higher expression (β-actin, Mdr1a, Mdr1b, Octn3, and Cnt1), lower expression 
(Oct1, Ent3, Cnt3, Ncbt1, Pept2, and β-casein), or similar expression (Mrp1, Octn1, 
Octn2, Ent1, Ent2, Cnt2, Ncbt2, Pept1, Mtx1, and Dmt1) of transporters relative to 
whole tissue extracts.   
Although no further studies were conducted to assess whether MEO or whole 
mammary gland best reflected the transport function of the mammary epithelium, such 
discrepancies may give insight into the tissue localization of these transporters. 
Expression levels that are higher or in certain instances similar between MEO and whole 
tissue may be indicative of transporters that are exclusively localized to the milk-
producing epithelia.  For instance, the iron transporter, Dmt1, is exclusively localized to 
the polarized epithelia of the mammary gland52 and shows similar expression levels 
between isolated MEO and whole tissue.  Therefore, whole tissue RNA data may be 
appropriate for evaluating proteins expressed in the major cell type of a tissue (i.e. MEO 
in the mammary gland).  On the other hand these results may be misleading for 
ubiquitously expressed transporters where the individual cell types of the mammary 
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gland each expresses their own compliment of transporters.  For instance, isolated 
adipocytes (a major component of the mammary gland) have active transport processes 
for glucose209, insulin and IGF-1210, vitamin C oxidation products211, vitamin D3 and 
E212, and calcium213.  Similarly, myoepithelial cells, which contribute to the milk-
ejection reflex, have transport mechanisms for manganese, calcium, and potassium214, 
215.   
Although several transporters may be localized to these secondary cell types in 
the mammary gland, the expression of transporters in isolated MEO underlies the 
primary site of nutrient transport into the mammary gland lumen.  Therefore, evaluating 
a whole tissue extract in an investigation of processes within the milk-producing cells of 
the mammary gland may either dilute the target RNA or contribute to the specific 
transporter RNA pool and yield erroneous, unreliable results.  However, we lack 
necessary scientific investigations into the localization of these transporters within the 
mammary gland.  Therefore, without immunohistochemical determination, or analyses 
of molecular markers that are specific to certain cell types (i.e. cytokeratins), such 
conclusions remain speculatory.  The remainder of this thesis work will focus on the 
transporter expression kinetics in mammary epithelial organoids (MEO), giving 
reference to the whole mammary gland only where applicable, since we are most 
concerned with the transport processes in the mammary epithelial cells and not the 
whole mammary gland. 
 
5.2.  Temporal Expression Patterns of ABC-Transporters Throughout Lactation in 
Mammary Epithelial Organoids 
 Transporters of the ATP-binding cassette superfamily (Mdr1a, Mdr1b, & Mrp1) 
follow a distinct decrease in expression throughout lactation.  Since these transporters 
serve to actively remove large lipophilic molecules and xenobiotics from the cell, this 
finding may provide insight into the protective mechanisms adapted at the mammary 
gland to safeguard neonatal health.  The decline in expression throughout lactation may 
not be protective for the mammary epithelia due to a decreased expression of the 
basolateral efflux proteins (i.e. Mrp1, which is expressed basolaterally in most other 
barrier epithelia), however is protective to the nursing neonate by limiting drug exit 
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through the apically expressed proteins (i.e. Mdr1a & Mdr1b) at the polarized mammary 
epithelium.  Furthermore, rat mammary gland tissue has its own compliment of drug 
metabolizing enzymes (cytochrome P450; CYP) and during pregnancy total CYP 
content increases significantly in the breast tissue and continues to rise and peak during 
lactation216, 217.  The increase in total CYP content includes the increase of many 
members of the CYP family, including CYP1A1, 2E1, 2D1, 2D3, 2D4, and 4A3.  
Conversely, there is a decrease in expression of many other CYP enzymes (CYP2A, 2B, 
and 3A).  However, these enzymes are present at low levels have been shown to 
undergo transcriptional upregulation if challenged with a xenobiotic insult216.  Despite a 
possible decrease in basolateral efflux transporter expression during lactation, the 
mammary epithelium has mechanisms to deal with xenobiotic insults that might arise.  
Such changes in xenobiotic metabolizing enzymes and transporter expression suggest 
the mammary gland undergoes substantial regulation.   
Little is known about the individual mechanisms for regulation of gene 
expression in the mammary gland. It is often avoided by mentioning the possibility of 
the mammary gland undergoing a complex process of endocrine regulation and since the 
mammary gland is a hormonally-driven system, it is clear that endocrine signals must 
play a part in regulation22.  However, with little information available on the effects of 
individual hormones on mammary gland processes (specifically protein-mediated 
transport) one cannot draw many direct correlations.  Substantial evidence has 
highlighted the importance of extracellular matrix (ECM) interactions in the regulation 
of gene expression in the mammary epithelial cell218-222.  The mammary gland ECM 
composition changes markedly with reproductive state223, presumably due to certain 
hormonal patterns. ECM components are known to be responsible for the regulation of 
intracellular P-glycoprotein mRNA (specifically laminin and collagen IV components of 
ECM)224, possibly due to cell-ECM interactions through cell surface receptors (i.e. 
integrins) which exploit a number of signal transduction pathways222, 225.  Therefore, as 
the mammary gland ECM environment matures, it may regulate the expression of many 
transporters through its interactions with cell surface receptors. 
 Taken together, these data demonstrate that the mammary gland reduces the 
expression of these important players in xenobiotic transport and disposition to limit 
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drug exposures to the neonate.  In addition, the mammary gland also upregulates its own 
compliment of drug metabolizing enzymes, some of which undergo transcriptional 
regulation in the face of a xenobiotic attack, which allows for the metabolism of 
xenobiotics that may enter the mammary epithelia.  The reduction in the mRNA levels 
of the ABC transporters is consistent with the primary role of the differentiated 
mammary epithelium to provide a nutrition source that preserves the health of the 
neonate (i.e. nutrition, immunology, bioactive agents, etc.) and relatively low levels of 
potentially harmful xenobiotics.  The decline in the expression of the ABC transporters 
indicates that all the resources of the epithelial cells are dedicated to providing nutrient-
rich and safe secretions.  This is strong evidence that the mammary gland has strictly 
evolved mechanisms to produce and provide an unparalleled nutrient source that meets 
the health needs of the developing offspring and therefore, breast milk is under most 
circumstances the safest form of infant nutrition. 
 
5.3.  Temporal Expression Patterns of SLC-Transporters Throughout Lactation in 
Mammary Epithelial Organoids 
5.3.1.  The Organic Cation Transporter Family (Oct) 
 The first member of the organic cation transporter family (Oct1) was the only 
member of this family to undergo significant changes between non-lactating and 
lactating mammary epithelial cells3 and therefore, was the only member of this family to 
be investigated. 
 Oct1 is a facilitated organic cation transporter88 that is expressed at the 
basolateral membrane of both the hepatocyte and the proximal tubule in the kidney88, 226.  
The expression of Oct1 in MEO is much lower than that observed in whole tissue giving 
an indication that Oct1 is expressed ubiquitously in the mammary gland as it’s 
expression in found in a wide range of tissue types202.  Oct1 expression in whole tissue 
indicates its critical endogenous role in the mammary gland in the later stages of 
lactation, possibly due to the mobilization/utilization of fat.  Oct1 has been shown 
recently to be capable of transporting prostaglandins227 and therefore, may be capable of 
transporting other positively charged fatty acid components involved in lipolysis in the 
mammary gland, however this claim has yet to be substantiated.  Oct1 in MEO 
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demonstrates that the facilitated transport of cations is critical in early lactation stages 
(L1 – L7) and of less importance in later stages of lactation (Figure 4.5).  Recently, the 
breast milk content of numerous micronutrients has been evaluated between colostrum 
and mature milk228, and the increase in some of these charged moieties may be due, at 
least in part, to the contributions of organic cation transporters, particularly following 
the establishment of tight junctions and the formation of a polarized mammary 
epithelium. 
5.3.2.  The Organic Cation/Carnitine Transporter Family (Octn) 
 The Octn family of transporters are responsible for the uptake of numerous 
charged cations, and are one of the primary transporter families which facilitate the 
uptake of dietary carnitine, a conditionally essential nutrient88, 89.  More importantly, the 
newborn is not capable of carnitine synthesis during the initial months of life229, 230, and 
must therefore rely solely on exogenous sources of carnitine during this period.  
Consequently, the transporters responsible for the accumulation of carnitine in breast 
milk are of critical importance. 
 Octn1 is the only member of the Octn family that uses a bi-directional transport 
mechanism that is independent of sodium88, whereas Octn2 and Octn3 are the proposed 
dominant players for carnitine transport which employ a sodium and pH-dependent 
mechanism88, 89.  Since Octn1 has a lower affinity to transport carnitine, and is a bi-
directional transporter, it may only play a very minor part in the flux of carnitine into 
breastmilk88.  Accordingly, MEO data shows a relatively constant expression level into 
late lactation, which seems reasonable for a facilitated transporter (Figure 4.6a).  
Knowledge of the localization of Octn1 at the apical or basolateral membrane of the 
polarized mammary epithelium will further clarify its role during lactation.  
Octn2 and Octn3 are the high88 and intermediate-affinity89 carnitine transporters 
respectively, and are therefore the most likely transporters responsible for the milk 
levels of carnitine.  Milk carnitine is constant for the first 3-weeks postpartum in 
humans where levels then significantly drop (almost in half) to remain lower and 
constant for the remainder of lactation231.  Similarly, mammary gland explants from 
lactating rats showed a significant drop in L-carnitine uptake from early lactation to late 
lactation232.  The mRNA expression pattern of Octn2 reflects this decline in both whole 
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mammary gland tissue and MEO and may therefore be the main contributor to milk 
carnitine status.  The expression pattern of Octn3 differs markedly as Octn3 increases 
steadily throughout lactation to greatly exceed Octn2 levels.  Since Octn3 is a relatively 
new transporter, there is substantially less literature available, however it has recently 
been reported that Octn3 is a transporter localized to the peroxisome233 of mammalian 
cells.  Since the peroxisome is a metabolic organelle, Octn3 may only play a critical role 
in transporting the chain-shortened products of lipid metabolism from the peroxisome 
back into the mammary gland cells233 and therefore may only contribute to cellular 
energy status and may not be a major contributor to the carnitine content of breast milk.   
 The tissue distribution of Octn3, the intermediate carnitine transporter233, is 
limited and has been shown to be almost exclusively expressed in the testis of mice234, 
the basolateral compartment of chicken enterocytes89, and localized to the peroxisome in 
human skin fibroblasts233.  Since its expression is very limited, it provides insight into 
its significant role in the mammary gland. However the identification of where Octn2 
and Octn3 are expressed in the polarized epithelium will help to clarify their roles 
during lactation. 
5.3.3.  The Concentrative Transport Family (Cnt) 
 The concentrative nucleoside transporters all share the same sodium-dependent, 
active transport mechanism.  However, the substrate profile for each transporter is 
slightly different.  Cnt1 transports the pyrimidine nucleosides and adenosine85, Cnt2 
transports the purine nucleosides, uridine85, and most recently has been shown to be a 
high-affinity adenosine transporter90, and lastly, Cnt3 transports both purine and 
pyrimidine nucleosides85.  In addition, the cellular localization of mammalian 
nucleoside transporters has been extensively reviewed and the exclusive expression of 
these transporters to the apical membrane of absorptive epithelia indicates their role in 
the apical uptake of nucleosides and nucleoside analogues235, 236.  However, this uptake 
role is not limited to absorptive epithelia (i.e. intestine).  Secretory epithelia, such as the 
renal and hepatic barriers, are responsible for the cellular removal of toxins.  Yet these 
barriers are still capable of lumen-facing cellular uptake of nucleosides and therefore, 
the cellular distribution and function of the nucleoside transporters is identical to that in 
the absorptive epithelia237, 238.  The universal cellular expression and function of 
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nucleoside transporters implies their role in the cellular accumulation of nucleosides, 
and the diversity in the substrate profile indicates a distinct role for each individual 
transporter. 
 Cnt1 mRNA increases steadily to mid-lactation where it remains relatively 
constant until involution in MEO. This expression appears to be primarily in the MEO 
as whole tissue levels of Cnt1 are nearly 100-fold lower (Figure 4.8A).  Since total 
nucleosides/nucleotides in milk tend to decrease over the course of lactation239, Cnt1 
must be involved with other endogenous roles within the mammary gland, possibly 
involving the low-affinity transport of adenosine or adenosine analogues such as cyclic-
AMP (cAMP).  Adenosine levels in human milk are relatively low (~16% of total 
potentially available nucleotides240, 241), however since Cnt1 is one of the only 
nucleoside transporter capable of the active transport of adenosine, it must play a role in 
determining adenosine concentrations in milk.  The adenosine analogue, cAMP, shows 
an increased binding affinity with pregnancy, which is further increased in lactation with 
highest levels in early involution242.  The increase in cAMP binding during pregnancy 
and involution is strongly associated with the level of cell proliferation and this is 
possibly representative of Cnt1 mRNA expression in MEO.  In addition, elevated levels 
of cAMP and accumulation in extracellular fluids in mouse mammary glands decreases 
the responsiveness of the epithelial cells to lactogenic hormones and turns off β-casein 
gene expression243, which may explain the marked increase in Cnt1 mRNA levels 
during involution.  Furthermore, cAMP has been shown to increase the ability of the 
small intestine to transport fructose without increasing GLUT mRNA levels244 and 
therefore, Cnt1 may play a role in modulating sugar uptake in the neonatal small 
intestine.  The possible role of Cnt1 in mediating cAMP transport has not been 
evaluated, however the ability of this transporter to accommodate numerous nucleoside 
analogues161 does indicate its diversity and possible capability of mediating cAMP 
transport. 
 The remaining nucleoside transporters, Cnt2 and Cnt3 follow a similar pattern of 
expression representative of the decline in total nucleosides in milk fractions throughout 
lactation239.  The dramatic upregulation of Cnt2 and Cnt3 during early lactation are 
likely indicative of the critical role nucleosides play in the nursing infant.  Feeding a 
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nucleoside and nucleotide mixture in addition to normal diet to male rats caused a 
significant increase in jejunal weight, protein and DNA content, villous height, and a 
decrease in tight junction size between enterocytes245.  Furthermore, dietary nucleosides 
caused an increase in B- and T-helper cell antigens in mice and contributed to the 
maturation of intestinal lymphocytes and ultimately intestinal immunity246.  In addition, 
Cnt2 has been shown to transport cyclic ADP-ribose (cADP-R), a calcium mobilizing 
second messenger247 which has been shown to modulate intracellular calcium status by 
activating calcium release through intracellular ryanodine receptors247.  Therefore Cnt2 
may also play a role in myoepithelial cell contraction by increasing the frequency of 
calcium sparks in the sarcoplasmic reticulum, leading to an increased frequency of 
myoepithelial cell contraction248 and a consequent increase in milk-ejection.  The ability 
of Cnt2 to transport adenosine was recently evaluated, and was shown to be the highest 
affinity transporter for the adenosine substrate90.  The role of adenosine in maintaining 
mammary gland functions is unknown.  However, adenosine has been shown to be a 
regulator of cellular proliferation in cardiac fibroblasts249 and vascular smooth muscle 
cells250.  It may be possible that intracellular accumulation of adenosine into mammary 
epithelial cells, via Cnt2, may decrease extracellular concentrations (where it 
accumulates during normal metabolic activity251), thereby promoting cell proliferation 
in the surrounding tissues (parallel to the correlation of Ent1 and cellular proliferation).  
The decrease thereafter, may allow for the extracellular accumulation of adenosine, 
which inhibits cellular proliferation249, 250.  On the other hand, Cnt2 may only be 
involved in the transepithelial flux of nucleosides into the breast milk and therefore, a 
major regulator of the adenosine composition in breast milk. 
 The limited tissue distribution of these transporters indicates the significance of 
their expression in the mammary gland, especially Cnt3, which is expressed at very low 
levels and in very few tissues compared to Cnt1 and Cnt2204.  Therefore these 
transporters must play a critical role in the mammary gland by providing critical 
nucleosides to the neonate, or regulating mammary epithelial cell status, or both.  
Recent research demonstrates that a differentiation stimulus (glucocorticoids) presented 
to rat intestinal epithelial cells sparked a significant increase in Cnt transporter function 
at all 3 functional levels, mRNA, protein, and activity for both Cnt1 and Cnt2252.  
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Therefore, the distinct patterns of Cnt expression, specifically Cnt1 and Cnt2, which 
may represent an increasing differentiation stimulus and an inhibiting proliferation 
stimulus (via adenosine) respectively, indicates a complex pattern of regulation which is 
not understood in the mammary gland.  Nevertheless, the capacity of these transporters 
to facilitate the transepithelial movement of nucleosides to assist in breast milk 
composition cannot be ignored.  Dietary nucleosides are involved in a number of key 
biochemical processes such as energy metabolism (ATP & GTP), coenzyme systems 
(FAD, NAD & NADPH) and second messenger systems (cAMP & cADP-R) and are 
considered conditionally essential to the nursing neonate due to the large energy 
demands of de novo synthesis253.  
5.3.4.  The Equilibrative Nucleoside Transport Family (Ent) 
 The equilibrative nucleoside transporters are proposed to work in tandem, as bi-
directional facilitators, with the Cnt’s to maintain nucleoside flux across the cell 
barrier86.  The tissue distribution of the Ent’s are similar where they are all ubiquitously 
expressed and they share similar substrate profiles, with the exception of Ent1 which 
transports purine and pyrimidine nucleosides but does not transport nucleobases86.   
 The temporal expression patterns of the Ent’s in the mammary gland are similar 
with the exception of Ent1, where Ent2 and Ent3 remain low in MEO and Ent1 is 
increased in early lactation.  Since Ent1 does not allow the transport of nucleobases, the 
increase in early lactation may indicate that the smaller purine and pyrimidine 
nucleosides are of greater importance during early lactation and the other transporters 
capable of nucleobase transport are kept low and relatively constant.  The altered 
expression of Ent1 may also reflect its coupled function to the Cnt transporters, Cnt2 
and Cnt3, which show a similar expression pattern.  However, such a relationship is 
purely speculatory.  A more plausible explanation is the increase in Ent1 mRNA 
reflecting the proliferating nature of the mammary gland in early lactation.  Isolated rat 
intestinal epithelial cells in the presence of a proliferative stimulus (EGF & TGF-α) 
showed a significant increase in Ent1 at mRNA, protein, and activity levels, however no 
alterations were visible for Ent2, at any functional level252.  Therefore, the pattern of 
Ent1 mRNA may be representative of the proliferative status of the mammary gland 
where the rapid proliferation may provide the mammary gland with a “stockpile” of 
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undifferentiated cells.  This “stockpile” can be accessed when older cells, near the end 
of their secretory lifespan, are sloughed off into the breast milk254, at which time the 
differentiation status of the mammary gland would increase (as evident from Cnt1 
data)252. 
 Interestingly, Ent1 and Ent2 expression levels and patterns are similar between 
whole tissue and MEO, whereas Ent3 is expressed in a much different manner.  The 
relative differences between whole tissue and MEO may give insight into the tissue 
specific expression of the Ent’s within the mammary gland.  Since the Ent’s are 
ubiquitously expressed, a subtle difference in whole tissue levels (marginally higher) 
may indicate that Ent1 and Ent2 are also expressed in a secondary tissue that does not 
comprise a large percentage of the mammary gland.  In the case of Ent3, it has recently 
been shown that Ent3 is localized to the intracellular membranes associated with the 
lysosome rather than the cell membrane as was originally proposed255.  If the increase in 
energy demands during lactation causes fat mobilization within the mammary gland 
tissue, the increase of Ent3 mRNA in whole tissue may not be surprising as lysosomes 
are involved in a number of metabolic pathways, including lipolysis256.  However, there 
is comparatively much less known about Ent3 than Ent1 and Ent2, and future studies are 
needed86, 255. 
5.3.5.  The Nucleobase Transporter Family (Ncbt) 
 The nucleobase transporter family was originally called as such due to an amino 
acid similarity with a mammalian nucleobase transporter257.  However, recent research 
suggests that the appropriate nomenclature remain as the sodium-dependent ascorbate 
transporters (SVCT) due to their inability to transport nucleobases258.  Nevertheless, 
GeneBank database searches for rat nucleobase transporters result in cDNA sequences 
of the Slc23a family, which also encodes the mammalian sodium-dependent ascorbate 
transporters.  With current research not supporting the Slc23a family’s ability to 
transport nucleobases258, it will be assumed that the nucleobase transporters are 
primarily ascorbate transporters and other mechanisms are involved in the transport of 
nucleobases in the mammary gland, similar to the mechanisms seen at the well 
characterized blood-testis barrier259. 
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 The levels of vitamin C in transition milk (colostrum) and mature milk are 
similar260 and only begin to decline during prolonged lactation261.  Therefore, transport 
mechanisms responsible for vitamin C should remain relatively constant for the majority 
of lactation and only decreasing into later stages, which is supported by the mRNA 
expression of the SVCT transporters in MEO.  Interestingly, the expression pattern in 
whole mammary gland tissue is similar for Ncbt2, however not for Ncbt1, which shows 
a dramatic increase into the late stages of lactation, indicating an important endogenous 
role in the mammary gland.  It was reported over two decades ago that the addition of 
ascorbic acid to rat smooth muscle cell culture systems altered the ECM matrix 
composition by increasing the ratio of collagen to elastin through reductions in 
elastin261.  Similarly, cultured calf aortic smooth muscle cells demonstrated a similar 
increase in ECM collagen to be the dominant matrix component (greater than 80%) with 
ascorbic acid feeding262.  In addition to modulating ECM composition in the calf smooth 
muscle cells, ascorbic acid feeding promoted the presence of poly(A+) RNA in the total 
RNA pool and therefore can modulate transcriptional changes in gene expression263.  
Both SVCT1 and SVCT2 demonstrate high affinity for L-ascorbic acid, with the latter 
transporter having a slightly higher affinity91.  The endogenous role that each of these 
transporters play in the mammary gland is unknown, however, it may be possible that 
Ncbt1 regulates L-ascorbic acid transport to alter ECM composition in preparation for 
involution by decreasing cell responsiveness to hormonal signalling264.  Further 
investigation is sorely needed. 
5.3.6.  The Oligopeptide Transporter Family (Pept) 
 The Pept transporters are a family of apically expressed transporters which are 
responsible for the uptake of small peptides from the lumen back into the cell for use in 
protein syntheis92.  The presence and localization of Pept2, the high-affinity, low 
capacity peptide transporter has been previously investigated in the mammary gland and 
both Pept2 mRNA and protein was localized exclusively to the secretory cells.  Pept2 is 
highly expressed at the apical cell compartment in numerous other tissues (i.e. kidney 
proximal tubule and choroids plexus265) and functions in the apical uptake of small 
peptides against an electrochemical gradient266.  The function of Pept2 in other tissues 
implies its role in the apical uptake of short-chain peptides in the mammary gland 
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possibly resulting from the hydrolysis of milk proteins for use within the epithelial 
cells73.  However, its role and expression throughout lactation is not understood.  It may 
be possible that Pept2 is upregulated in early lactation to limit the presence of specific 
peptides in the milk until the gastrointestinal tract of the neonate adequately matures.  
Once the neonate intestinal system is ready, Pept2 may be limited to providing these 
specific small peptides to the epithelial cells of the mammary gland as the protein 
concentration of milk begins to increase throughout lactation267. Alternatively, Pept2 
may merely provide the secretory mammary epithelial cells with specific proteins to 
maintain proper cell function73.   
 On the other hand, the low-affinity, high capacity peptide transporter, Pept1, 
shows low expression throughout lactation with mRNA levels spiking during 
involution.  Pept1 is also expressed at the apical cell compartment in the renal proximal 
tubules268 and enterocytes269 and is involved in the apical uptake of short chain peptides 
in a similar manner to Pept2.  Pept1 may also be responsible for the uptake of a wide 
range of milk proteins from the mammary gland lumen, as it works in concert with 
Pept2.  The spike in Pept1 mRNA in involution may imply its role in the less-selective 
uptake of milk proteins from the lumen in preparation for involution.  However, these 
claims are speculatory and require further investigation.  
5.3.7.  The Methotrexate Carrier (Mtx1) 
 The methotrexate carrier (Mtx1) is the rat ortholog of the human reduced folate 
carrier and is responsible for the uptake of folate and anti-folates (i.e. methotrexate) in a 
sodium-dependent manner93.  Folate is responsible for the maintenance of new cells, and 
is therefore critical in developmental stages where rapid cell division occurs (i.e. early 
life) due to its role in facilitating the replication of DNA270.  The folate concentration in 
human milk varies greatly, however in all cases milk levels of folate increase throughout 
lactation, increase throughout the day, and increase in the transition from foremilk to 
hindmilk271, 272.  The temporal expression of Mtx1 mRNA shows a continual increase 
until mid lactation where it begins to decline.  It is not unreasonable to assume that the 
protein levels of Mtx1 remain elevated even after the gradual removal of the protein 
message (mRNA). 
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 Conversely, the message encoding the methotrexate carrier in MEO may indicate 
its role within the proliferating mammary gland.  Since folate is involved in cell 
proliferation, the increase in Mtx1 may indicate the needs of the mammary gland to 
support active cell proliferation during lactation.  Throughout lactation, the mammary 
gland evacuates mammary epithelial cells that are near the end of their secretory 
lifespan and lays down new cell layers to maintain this rotation of cells254.  Even though 
the total cell content of milk declines over lactation, and despite large interindividual 
variations273, the percentage of total epithelial cell content tends to increase into mid 
lactation in humans273.  The removal of older secretory cells to accommodate the newly 
proliferated cells may substantiate an endogenous role of folate to aid in the 
proliferation of the new secretory cells, similar to the possible role that Ent1 plays in 
active cell proliferation in early lactation.  The decline into late lactation may indicate 
that there is a decrease in the proliferation of secretory cells and consequently may be a 
preparatory phase for the impending involution. 
5.3.8.  The Divalent Metal Transporter (Dmt1) 
 Dmt1 serves to actively transport non-heme (ferrous) iron into the breastmilk52, 
53 and is among the very few transporters which have been critically evaluated at the 
lactating mammary epithelia.  The milk iron concentrations54, 274, Dmt1 mRNA50-52, and 
Dmt1 protein levels50-52 all decline throughout lactation, and milk iron concentrations 
are highly regulated to be nearly independent of maternal iron status52.  The decline in 
Dmt1 mRNA in previously published reports52 was evaluated using a whole mammary 
gland RNA sample and is reflected in our results using whole tissue MEO.  However, 
our whole tissue mRNA expression only marginally matches the previously published 
results.  Although this is curious, an explanation may be hidden in the methodology.  
Previously published reports indicate that a subcutaneous dose of oxytocin was 
administered to stimulate milk let-down and a fraction of milk (~1mL) was taken from 
each animal prior to mammary gland excision52 which may have limited luminal milk 
content.  Our methodology did not involve milk removal.  Since milk is composed of 
numerous, viable epithelial cells254, 273, our whole tissue samples would have contained 
traces of milk52 and blood fluids275 that may have contributed to the Dmt1 signal, 
limiting the degree of similarity between previously published reports.  Conversely, our 
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MEO samples were void of any milk or blood fluids and match previously published 
data.  Since our whole tissue data was obtained using only a small section of mammary 
gland that may have had traces of milk and/or blood fluids, it is not surprising that our 
data does not match literature reports.   
 Using immunohistochemistry, Dmt1 was shown to be localized to the milk 
secretory cells and not present in the myoepithelial cells in the mammary gland52.  
Similarities with our MEO data may suggest that a whole tissue RNA sample might be 
appropriate in evaluating transporters that are localized to the milk-producing cells of 
the mammary gland.   However, few other transporters have been evaluated in the 
mammary gland and therefore, each transporter would require a full characterization to 
substantiate this relationship. 
5.3.9.  The Milk Protein β-Casein 
 β-casein is a milk-specific protein that is expressed in the mammary gland 
during lactogenesis phase I and II22 where mRNA levels increase significantly from 
virgin levels and remain elevated throughout the first 10-14 days of lactation where after 
it then begins to decline276.  β-casein expression is dependent on ECM-cell adhesion 
interactions through the β-integrin signaling pathway277 (more specifically, the 
interaction between these β-integrins and the extracellular component, laminin) and cell-
cell contact277.  Our whole tissue mRNA analysis shows a similar pattern of expression 
as seen in previous studies involving mRNA analysis276, however our MEO data is far 
from equivalent.  Possibly the procedure employed to isolate MEO from whole 
mammary gland tissue is sufficiently long and rigorous to nearly abolish milk protein 
expression by removing ECM-cell and cell-cell contacts.  The critical interactions 
between ECM components and cell-surface receptors are processed by the cell within a 
few short hours277.  The processing time for the isolation of MEO from whole mammary 
gland tissue is approximately 9 hours, during which, the dissociation of ECM-cell and 
cell-cell contact may turn off milk protein expression.  Therefore, it appears that a whole 
tissue RNA analysis may be the most reliable way to evaluate milk-protein expression 
as organ architecture is preserved until RNA analysis.   
 Furthermore, a fresh, whole tissue preparation does contain luminal milk which 
is in part composed of viable mammary epithelial cells254. In some species (i.e. human) 
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these cells comprise over 90% of total milk cell counts273.  These viable cells (nearly 
100% viable in humans273) have been used in similar transporter evaluations using 
human milk3, and have been used as a primary mammary epithelial source for cell 
culture and the evaluation of milk proteins such as the casein proteins278.  Since these 
sloughed mammary epithelial cells are only present in a whole mammary gland 
preparation, we cannot ignore their contribution to the total RNA pool.  Therefore, the 
results may not be representative of the β-casein protein expression in the polarized 
mammary epithelial cells of the mammary gland. 
5.4.  Temporal Expression Patterns In MEO: A Far Superior Tissue Source? 
 The temporal mRNA expression levels of transporters from the ATP-binding 
cassette family (ABC) and the solute carrier family (SLC) exhibit some differences 
between whole mammary gland tissue and isolated milk-producing cells (MEO) for the 
majority of transporters analyzed. These differences bring into question to what extent, 
if any, the isolation procedure might alter gene expression and to what extent the 
heterogeneous population of cells in the whole mammary gland influences expression 
patterns and levels of transporters in the mammary epithelium per se.  It appears that the 
isolation procedure did not significantly alter transporter expression as evidenced from 
previously evaluated transporters at the lactating rat mammary gland52.  Furthermore, 
the ability of a rigorous isolation procedure to alter gene mRNA expression was recently 
evaluated using whole liver tissue samples and isolated hepatocytes279.  This rigorous 
isolation involving enzymatic digestion, did not affect gene mRNA expression279.  One 
exception to this conclusion may be utility of using isolated MEO in the evaluation of 
milk-protein expression throughout lactation.  Since milk-protein synthesis is rapidly 
regulated through cellular interactions with neighboring cells and extracellular matrix 
components (i.e. laminin)277, 280, the removal of these interactions may rapidly alter 
cellular signaling.  Consequently, MEO preparations may not allow for reasonable 
assessments of milk proteins. 
 With the possible exception of the milk protein, β-casein, our results, in addition 
to the remarkable similarities from previously published mammary gland reports52 have 
lead us to believe that isolated MEO from whole mammary gland tissue may be a far 
superior tissue source for the evaluation of nutrient transporters during lactation.  
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Intuitively, of course, the isolated MEO seem to be a far superior choice as they are void 
of secondary mammary gland cell types and composed primarily of milk-producing 
epithelial cells, the key cell type in the evaluation of solute transporter across the 
mammary epithelia.  However, MEO require much further characterization to 
substantiate this belief.  Nevertheless, assuming our hypothesis is correct, the expression 
patterns of nutrient transporters from the ABC and SLC transporter superfamily in 
isolated MEO from whole mammary gland tissue follow 1 of 4 distinct temporal 
expression patterns throughout lactation: steadily decreasing throughout lactation 
(Mdr1a, Mdr1b, Mrp1 & Dmt1), increasing in early lactation and decreasing thereafter 
(Oct1, Octn2, Ent1, Cnt2, Cnt3, Pept2 & Mtx1), steadily increasing throughout lactation 
(Octn3 & Cnt1), and a relatively constant expression throughout lactation (Octn1, Ent2, 
Ent3, Ncbt1, Ncbt2 & Pept1).  The distinct expression pattern may give insight into the 
temporal role of these transporters in establishing the maternal milk composition. 
5.4.1.  Decreased Temporal Expression Throughout Lactation 
 The only member of the SLC-transporter superfamily that undergoes a decline in 
expression in MEO throughout lactation is the divalent metal transporter, Dmt1.  Dmt1 
has previously been investigated in the mammary gland and the decline in Dmt1 mRNA 
is accompanied by a similar decline in Dmt1 protein50-52 and in iron milk levels54, 274.  
The decline in all 3 elements of mammary gland iron begs the question of how the 
neonate responds to the decline of milk iron.  The neonate is a very plastic system and 
undergoes many developmental changes in response to a number of stimuli, including 
nutritional stimuli.  The decline in mammary gland iron status is accompanied by a 
gradual increase in intestinal iron transporters in the neonate in both rats50, 51 and 
mice281.  Therefore, the nutritional composition of the maternal milk may in fact be a 
signaling mechanism to the neonate to develop its own compliment of nutritional 
transporters.  When iron status is high, neonate iron transporters are low, but the 
progression to a low iron status in the milk forces an upregulation of neonate iron 
transporters, a factor affecting the proper ontogeny of the neonatal system.  
Consequently, the expression pattern of nutrient transporters at the lactating mammary 
gland may be a mechanism to modulate the proper ontogeny of the neonatal system. 
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5.4.2.  Increased Temporal Expression in Early Lactation 
 Nutrient transporters that increase transiently during early lactation and decline 
thereafter are members from the organic cation transporter family (Oct1), organic 
cation/carnitine transporter family (Octn2), nucleoside transporter family (Ent1, Cnt2, 
Cnt3), oligopeptide transporter family (Pept2) and the methotrexate carrier (Mtx1).  The 
transient increase in these transporters may imply their role to actively accumulate 
critical compounds, which are main players in development (i.e. carnitine, nucleosides, 
peptides, and folate), into the breast milk during very early development to ensure 
sufficient levels are received by the nursing neonate.  Levels declining thereafter may 
indicate a possible regulatory role (similar to that seen in the ontogeny of Dmt150, 51) in 
modulating the ontogeny of the neonatal system.  For instance, the mRNA levels of both 
Oct1 and Octn2 in the kidney (the site of highest expression202) increase postnatally, 
with levels initially very low and increasing gradually throughout suckling202.  
Similarly, mRNA levels and protein levels of Pept2 in the developing kidney show a 
similar pattern of development but at a much quicker rate282, possibly reflecting the 
rapid changes in mammary gland mRNA levels.  On the other hand, the intestinal 
development of Octn2 does not conform to this relationship.  Octn2 mRNA and activity 
levels in the jejunum and ileum are significantly higher than adult values at birth and 
they decrease postnatally throughout the lactation period283, where neither elimination of 
suckling, nor exogenous carnitine supplementation could alter the developmental 
expression pattern283.  The adult levels of Octn2 increase distally in the small 
intestine202, and the ontogeny of Octn2 at the duodenum is not known.  Distal intestine 
regulation of Octn2 does not support the possible ontogeny-signaling mechanism of 
lactation, which is largely supported by the renal ontogeny of Octn2, Oct1, and Pept2, 
however we must consider the possibility of other transporters influencing the ontogeny 
by providing a nutrient stimulus (i.e. Octn3 ensuring proper carnitine levels as its 
expression continues to increase).  However, the ontogeny of the remaining transporters 
has yet to be investigated.  In addition, nutrients such as carnitine are conditionally 
essential and with time, the neonate develops the capacity to synthesize its own 
endogenous stores229, 230.  Therefore, even though the ontogeny of carnitine transporters 
to not correspond to the mammary gland expression patterns, the availability of carnitine 
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in the milk will ultimately play a role in the ontogeny of carnitine synthesis in the 
neonate. 
5.4.3.  Increased Temporal Expression Throughout Lactation 
 Nutrient transporters that increase as lactation progresses are Cnt1 and Octn3.  
The ontogeny of these transporters is not known in other tissues and since their roles 
within the mammary gland are purely speculatory, their role in neonatal development is 
unknown.  These transporters may contribute to milk composition of critical nutrients 
and play an important role in neonatal development. Furthermore, they may play a 
pivotal role in maintaining proper mammary gland functions in the later stages of 
lactation. 
5.4.4.  Constant Temporal Expression Throughout Lactation 
 The nutrient transporters that remain relatively constant throughout lactation are 
members of the organic cation/carnitine transporter family (Octn1), the equilibrative 
nucleoside transporter family (Ent2 & Ent3), the nucleobase transporter family (Ncbt1 
& Ncbt2) and the oligopeptide transporter family (Pept1).  The majority of these 
transporters are facilitators (Octn188, Ent2 & Ent386) or low affinity transporters 
(Pept192) and may only be expressed to maintain substrate flux across the mammary 
epithelial barrier.  Interestingly, Octn1 mRNA levels in the kidney undergo a similar 
ontogeny as Octn2 and shows similar intestine expression patterns (increase distally) yet 
is expressed at much lower levels202.  In addition, Octn1 levels are ubiquitously 
expressed at more consistent levels than the Octn2 transporter202.  The role that Octn1 in 
the mammary gland may play in determining the proper ontogeny in the neonate is 
unknown.  Conversely, the ontogeny of Pept1 mRNA in the neonatal intestine, and 
protein levels in the kidney have been evaluated282.  The mRNA and protein levels in all 
3 parts of the small intestine increases postnatally and spikes around day 5 of lactation 
and decreases thereafter to reach a lower, stable expression level282 which does not 
support the potential relationship between Pept1 in the mammary gland modulating 
neonatal ontogeny.  Therefore, the facilitated transporters may merely maintain 
substrate flux across the mammary epithelial cells and the ontogeny of these transporters 
may be predetermined. 
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5.5.  Temporal Expression Patterns as Predictors of Transporter Importance & 
Nutritional Status in the Neonate 
 The temporal expression patterns in lactating mammary epithelial cells may play 
a significant role in determining the optimal composition of maternal milk, and in 
addition, may modulate the proper ontogeny of the neonatal system.  If the latter 
proposition is correct, any manipulation of the nutrient transporters, either by maternal 
nutrition status or inhibition by exogenous compounds, will compromise the maternal 
composition of breast milk. This may ultimately result in an altered nutritional status 
leading to altered metabolic programming and ontogeny in the neonate.  Furthermore, 
the temporal expression pattern may predict when a nutritional or exogenous modulation 
of transporter function is not only possible, but at which stage of lactation it may be 
extremely detrimental by interfering with important transporter functions.  For instance, 
those transporters upregulated in early lactation imply a critical role in determining 
breast milk composition where any manipulation of transporter function may be 
detrimental. 
5.5.1.  Xenobiotics as Modulators of Maternal Nutrition Status 
 The ability of exogenous xenobiotics to alter the nutrient composition of 
maternal milk through competitive or noncompetitive reversible interactions has not 
been investigated.  However, I have previously discussed the shared substrate profile of 
nutrient transporters between nutrients and clinically relevant xenobiotics155, 157-161.  If 
nutrient transporters have the ability to transport xenobiotics, then there certainly does 
exist the possibility of having a xenobiotic-nutrient transporter interaction that decreases 
the transport of a critical nutrient substrate, which may result in a micronutrient 
deficiency.  Therefore, it is imperative that a system be developed to screen such 
interactions. 
 
5.6.  Primary Mammary Epithelial Organoid (MEO) Cell Culture System 
 MEO isolated from female Sprague-Dawley rats at day 1 and day 10 of lactation 
were cultured in an extracellular matrix-rich environment as previously described185, 193. 
This was done to address the question to what extent primary mammary alveolar 
epithelial cells maintain transporter expression levels at the mRNA level and the culture 
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conditions necessary to maintain expression levels to provide a possible model for in 
vitro transporter uptake studies.  The mRNA expression levels decreased throughout the 
plating period for Mrp1, Cnt3, and β-casein in both early and mid-lactation stage MEO, 
and the expression pattern of Octn2, Ent1, and Pept2 increased transiently by day 4 of 
culture and decreased thereafter in both MEO preparations.  Octn3 followed a far 
different expression pattern as it continued to increase until day 8 of culture in early 
stage MEO and remained more stable in later differentiated cells.  All transporter 
expression changes occurred at a much smaller degree in the MEO isolated from day 10 
of lactation with the exception of the milk-protein β-casein indicating that the ECM 
environment in culture may have had a large influence on gene expression.  Previous 
reports have cultured isolated MEO from virgin animals, which undergo significant 
proliferation, differentiation, and ductal morphogenesis in a sandwich culture of ECM 
proteins (Engelbreth-Holm-Swarm matrix (EHS); Matrigel™) with appropriate 
hormonal culture medium185-189.  No studies to date have used this culture system to 
evaluate MEO isolated from lactating rats.  It may be possible that the hormone-rich 
medium induces appropriate changes in the EHS matrix composition, or induces 
appropriate changes in the cellular architecture of organoids isolated from virgin 
animals, however such information is not available.  Regardless of the mechanism, 
lactating MEO in EHS matrix does not perform as well as virgin MEO using the exact 
same culture conditions as evidence by the lack of β-casein gene expression. 
 The ECM matrix composition of the mammary gland differs depending on the 
maternal reproductive state (i.e. pregnancy, lactation, involution, or quiescent), where 
the ECM proteins laminin, tenascin, fibronectin, and clusterin223 all change between 
pregnancy, lactation, and involution.  It may be possible that the changes in ECM 
protein levels also change throughout suckling and therefore an ECM created from the 
EHS sarcoma (i.e. Matrigel™) may not match the composition of mammary gland 
ECM.  In fact, the mammary ECM matrix has been shown to have up to a 50-fold higher 
fibronectin to laminin ratio than EHS matrix, which may better resemble the ECM 
composition that the mammary epithelial ductal tree is embedded in in vivo223.  
Accordingly, MEO cultured using an ECM composition of equal parts control matrix 
(EHS) and mammary gland matrix showed more favorable morphology than those 
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cultured on EHS matrix alone indicating that mammary gland matrix may be a far better 
cell medium for the culture and maintenance of mammary organoids223. 
 On the other hand, the extracellular matrix composition may not be the 
governing factor in the maintenance of gene expression in vitro.  After examining the 
temporal gene expression through the duration of culture, it became apparent that some 
of the expression patterns in vitro followed a similar pattern of expression in vivo 
(Mrp1, Octn2, Octn3, Cnt3, & β-casein), particularly in the young differentiated cells 
(lactation day 1).  The similarities in expression patterns regardless of the physiological 
space (i.e. in vivo or in vitro) may indicate a predetermined genetic program governing 
gene expression.  In fact, this idea has previously been proposed for the mammary 
epithelial cells during lactation284.  This “alveolar switch” implies that transcription 
factors (possibly encoding a cell-cycle protein; Elf5284 or Notch285) involved in 
coordinating the proliferation of mammary gland stem cells also play a key role in 
determining cell fate decisions.  Therefore, the regulation of stem cell fate to either a 
secretory or non-secretory cell may predispose the cell to certain regulatory patterns, 
including gene expression, and consequently the cells may coordinate gene expression 
nearly independent of exogenous influences (i.e. tissue processing & culture conditions). 
 Nevertheless, all transporters evaluated maintained an mRNA signal at 
reasonable levels by day 4 of culture, which was reflected in the microscopic 
appearance of MEO, as they appeared to maintain cellular architecture up until day 4 of 
culture (Figure 4.15). Therefore, the cell culture conditions may need some 
modifications to create a more relevant cell culture system, as they currently do not 
accurately reflect in vivo mammary gland conditions.  It would be beneficial to find a 
culture condition where transporter mRNA was maintained at a constant level for longer 
culture durations to facilitate the practicality of the methodology and the ability to 
extrapolate results as it is used to screen potential xenobiotic-transporter interactions in 
vitro as observed in other primary isolated cell systems.  However, the current cell 
culture system does allow for the maintenance of transporter mRNA expression.  This is 
consistent with the hypothesis that an ECM-rich culture environment will maintain 
transporter mRNA expression, at least at reasonable levels.  Therefore, isolated MEO 
cultured in an ECM-rich environment for a short culture duration period has the 
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potential to serve as a rapid screening tool if used immediately post-isolation. More 
investigation is required to develop culture conditions that allow for prolonged culture 
durations and maintenance of transporter expression levels.   
 
5.7.  Limitations & Pitfalls 
 Quantitative real-time reverse transcription polymerase chain reaction (QRT-
PCR) is considered the benchmark technique for the evaluation of mRNA transcripts for 
its striking sensitivity196, 286 and relatively low costs compared to microchip analyses287, 
288.  QRT-PCR is often done using two-reactions-two-tubes, or two-reactions-one-
tube196, and thus eliminates the need for “older” technologies that quantify transcripts 
using electrophoresis (i.e. northern blotting).  However, despite the sensitivity, 
occasionally there is the need to pool tissue samples due to limited tissue availability or 
limited mRNA availability from selected tissue sources; the latter plagued this research.  
Therefore, to maximize resources, I had to pool samples at the MEO stage and extract 
total RNA thereafter.  The method of “pooling” is not new to gene analysis, and is 
common-place when using more expensive analysis techniques such as microchip 
assays (recently reviewed288, 289).  These reviews provide great insight into the 
effectiveness of appropriately pooled samples, and when pooled appropriately, allow for 
adequate statistical power (in addition to the marked cost reductions)288, 289.  Recently 
reviewed by Kendziorski et al. (2003)288, the technique of pooling was assessed using 
RT-PCR techniques.  Using the more sensitive QRT-PCR analysis method, pooled 
samples from individuals did not introduce bias and resulted in averages that were 
extremely close to the means of individual analyses, with far less variation288.  However, 
the variations in such pooled analyses are considered only to represent experimental 
variability and do not truly represent biological variation.  Nevertheless, the findings 
indicate that using pooled mRNA samples with RT-PCR, one can obtain accurate 
results, representative of the population average288, 289.  Even though a pooled sample 
allows for such accuracy, improper pooling can tremendously favor outliers, due, at 
least in part to the possibility of unequal sample sizes prior to pooling.  Despite an 
attempt to eliminate this confounder, the role it may have played cannot be ignored. 
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 Further potential pitfalls exist in the relationship between relative mRNA levels 
compared with those of controls.  A marked change in mRNA levels does not always 
correlate with a similar magnitude of change in transporter protein or transporter 
activity.  Therefore, further studies are warranted to investigate the alterations in 
transporter protein levels and activity, in order to fully characterize the temporal 
dynamics of the transporters throughout lactation.  
 
5.8.  Conclusion 
 My thesis work evaluated the constitutive expression of 3 drug transporters and 
17 nutrient transporting proteins (including the milk protein β-casein) in mammary 
epithelial organoids (MEO), and compared that expression with whole mammary gland 
tissue isolated from female Sprague-Dawley rats at various stages of pregnancy, 
lactation, and involution.  The temporal mRNA expression patterns and levels of 
transporters differ between the two tissue preparations for most transporters evaluated, 
possibly due to a heterogeneous cell population in the whole mammary gland sections or 
due to the presence of milk or blood fluids that is not present in the isolated MEO 
samples.  The magnitude of the role that viable, sloughed cells in milk fractions may 
play in contributing to whole tissue mRNA analysis is unknown.  However, the 
presence of these cells will unquestionably contribute to the total RNA pool254, 273, 278.  
Similarly, blood fractions that remain in the mammary gland can also contribute to the 
total RNA pool275, and without perfusing the mammary gland prior to extraction, these 
fluid fractions will consistently add to the RNA pool in whole tissue samples.  
Therefore, since the MEO preparations are void of any fluid and cellular 
contaminants185 and better represent the physical barrier between the maternal system 
and the breast milk, the mRNA profiling of each transporter in the MEO may allow for a 
more accurate evaluation of transporter functions at the lactating mammary gland.  
Furthermore, the unique temporal expression patterns of transporters in MEO may 
provide better insight into the critical windows of nutrient delivery, and the mechanisms 
of the nutrient transport across the mammary epithelia for their accumulation in breast 
milk.   
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 The decreased expression of the ABC-transporters (Mdr & Mrp) implies a 
regulatory role in limiting drug exposures to the neonate.  In addition, the down-
regulation also demonstrates that the mammary gland is highly resourceful, conserving 
cellular economy by dedicating itself to providing nutrient-rich secretions and wastes no 
expense on transporters that do not contribute to this pivotal role.  The decreased 
expression of Dmt1, the only SLC-transporter to undergo this expression pattern, is 
paralleled by similar decreases in Dmt1 protein levels50-52, activity levels50-52 and 
consequently milk iron levels54, 274.  The decline of this transporter at all 3 functional 
levels is reflected in the neonate as the expression of its own compliment of iron 
transporters increases post-natally50, 51, 281, which may indicate that the mammary gland 
regulation of milk composition is a critical signaling mechanism to the neonate to 
upregulate its own compliment of transport proteins. 
 The increased expression of SLC-transporters in early lactation (Oct1, Octn2, 
Ent1, Cnt2, Cnt3, Pept2 & Mtx1) may imply their role to actively accumulate critical 
compounds that are responsible for ensuring proper development (i.e. carnitine, 
nucleosides, peptides, and folate) into the breast milk during very early developmental 
stages.  The decrease in transporter expression thereafter may indicate a possible 
regulatory role (similar to that seen in the ontogeny of Dmt150, 51) in modulating the 
ontogeny of the neonatal system.  However, a similar ontogeny-relationship does not 
exist for some of these transporters (i.e. Octn2283).  One must consider the possibility of 
other transporters influencing the ontogeny by providing adequate nutrient stimulus (i.e. 
Octn1 & Octn3 ensuring proper carnitine levels).  Therefore, the increase in Cnt1 and 
Octn3 throughout lactation may fulfill this role by providing the breast milk with 
adequate levels of nucleosides and carnitine, respectively.  Furthermore, they may also 
serve to maintain proper mammary gland functions and thereby play a dual role within 
the mammary epithelia. 
 The relatively constant expression of Octn1, Ent2, Ent3, Ncbt1, Ncbt2, and 
Pept1 may indicate their role to maintain substrate flux across the mammary gland 
epithelia.  Certainly, their role in other tissues as facilitators (Octn188, Ent2 & Ent386)  or 
low-affinity transporters (Pept192) supports this idea.  In addition, the lack of agreement 
between mammary gland regulation and the ontogeny of these some of these 
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transporters (i.e. Octn1202 & Pept1282) further supports the role that all members of a 
transporter family collectively, and not independently, influence ontogeny.   
 The complex regulation of transporters allows for the optimal nutrient 
composition of the breast milk, a composition that has the potential to influence the 
proper ontogeny of the neonatal system.  Although the mammary gland limits 
xenobiotic exposure through the down-regulation of drug transporters and up-regulation 
of drug metabolizing enzymes, the threat remains that xenobiotics may occupy nutrient 
transporters and influence milk nutrient composition thereby leading to a reorganization 
of the neonatal system.  Therefore, a reliable screening tool to evaluate this possibility 
would prove to be an invaluable resource for ensuring the health of the neonate.  The 
current primary MEO cell culture system does not accurately reflect the in vivo 
mammary gland environment.  However, it does allow for the maintenance of 
transporter expression at reasonable levels.  If used immediately post-isolation, this 
system may provide a useful tool to evaluate the threat of a xenobiotic-transporter 
interaction at the lactating mammary gland, adding another dimension to ensuring 
neonatal health and well being. 
Although this thesis work made a small but important contribution to our 
understanding of transporter expression in lactating mammary epithelial cells, many 
unanswered questions remain about transporter function and regulation throughout 
lactation. 
 
5.9.  Future Directions 
 mRNA expression profiling of various nutrient transporters throughout lactation 
is merely one small contribution to our understanding of mammary gland functions.  
Further investigations of the cellular/subcellular localization and activity characteristics 
of the mammary gland transporters are sorely needed to fully understand their roles in 
the transepithelial movement of nutrients into the breast milk.  Furthermore, the 
xenobiotic substrate profile of these nutrient-based transporters will provide insight into 
the possibilities of xenobiotic-nutrient transporter inhibition.  Screening for these 
interactions will add another assessment tool to help safeguard infant health by 
preserving the high quality composition of breast milk. 
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